Loading...

Kavanaugh, Arthur

Title(s)Professor, Medicine
SchoolRheumatology
Address9500 Gilman Drive #0943
La Jolla CA 92093
Phone858-657-7044
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    St. Louis University Medical School, St. Louis, MOMD
    Massachusetts Institute of Technology, Cambridge, MAABBiology

    Collapse Overview 
    Collapse Overview
    Research Interests
    Innovative strategies for the treatment of patients with rheumatoid arthritis and other rheumatic diseases. Prognostic and predictive factors for outcomes in rheumatic diseases. Research program on innovative approaches to various immunologic diseases, particularly novel biologic therapies.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial. Value Health. 2020 Oct; 23(10):1286-1291. Husni ME, Kavanaugh A, Chan EKH, Peterson S, Li N, Hsia EC, Kim L, Lo KH, Harrison DD, Han C. PMID: 33032771.
      View in: PubMed   Mentions:    Fields:    
    2. Psoriatic arthritis: exploring the occurrence of sleep disturbances, fatigue, and depression and their correlates. Arthritis Res Ther. 2020 Aug 26; 22(1):198. Haugeberg G, Hoff M, Kavanaugh A, Michelsen B. PMID: 32847612.
      View in: PubMed   Mentions:    Fields:    
    3. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2020 Jul 30. Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Siegel M, Stoff B, Strober B, Wu JJ, Hariharan V, Menter A. PMID: 32738429.
      View in: PubMed   Mentions: 1     Fields:    
    4. Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. ACR Open Rheumatol. 2020 Jul 25. Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, Paris M, Delev N, Teng L, Wollenhaupt J. PMID: 32710493.
      View in: PubMed   Mentions:
    5. Perceived influence of health status on sexual activity in patients with psoriatic arthritis. Scand J Rheumatol. 2020 Jul 16; 1-8. Haugeberg G, Michelsen B, Østensen M, Kavanaugh A. PMID: 32669024.
      View in: PubMed   Mentions:    Fields:    
    6. Birth Outcomes and Disease Activity During Pregnancy in a Prospective Cohort of Women With Psoriatic Arthritis and Ankylosing Spondylitis. Arthritis Care Res (Hoboken). 2020 Jul; 72(7):1029-1037. Smith CJF, Bandoli G, Kavanaugh A, Chambers CD. PMID: 31074583.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. GRAPPA Treatment Recommendations: Updates and Methods. J Rheumatol Suppl. 2020 Jun; 96:41-45. Kavanaugh A, Coates LC, van der Windt DA, Corp N, Soriano ER. PMID: 32482767.
      View in: PubMed   Mentions:    Fields:    
    8. Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2020 Jun; 72(6):806-813. Husni ME, Kavanaugh A, Murphy F, Rekalov D, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC. PMID: 30980514.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    9. Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials. Clin Exp Rheumatol. 2020 May 11. Tillett W, Lin CY, Trevelin Sprabery A, Birt J, Kavanaugh A. PMID: 32452352.
      View in: PubMed   Mentions:    Fields:    
    10. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020 05 09; 395(10235):1496-1505. McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, Masmitja JG, Goupille P, Korotaeva T, Gottlieb AB, Martin R, Ding K, Pellet P, Mpofu S, Pricop L. PMID: 32386593.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    11. Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. Arthritis Care Res (Hoboken). 2020 Jun; 72(6):814-821. Mease PJ, Gladman DD, Ogdie A, Coates LC, Behrens F, Kavanaugh A, McInnes I, Queiro R, Guerette B, Brunori M, Teng L, Smolen JS. PMID: 31909868.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    12. Imbalance Between Omega-6 and Omega-3 Derived Bioactive Lipids in Arthritis in the Elderly. J Gerontol A Biol Sci Med Sci. 2020 May 03. Coras R, Pedersen B, Narasimhan R, Brandy A, Mateo L, Prior A, Kavanaugh A, Armando AM, Jain M, Quehenberger O, Martinez M, Guma M. PMID: 32361743.
      View in: PubMed   Mentions:    Fields:    
    13. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era. RMD Open. 2020 05; 6(1). Haugeberg G, Michelsen B, Kavanaugh A. PMID: 32409518.
      View in: PubMed   Mentions:
    14. Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis. Clin Transl Sci. 2020 Jul; 13(4):743-751. Paul S, Marotte H, Kavanaugh A, Goupille P, Kvien TK, de Longueville M, Mulleman D, Sandborn WJ, Vande Casteele N. PMID: 32100960.
      View in: PubMed   Mentions:    Fields:    
    15. High impact of burnout on rheumatology practitioners. J Rheumatol. 2020 Apr 01. Tiwari V, Kavanaugh A, Martin G, Bergman M. PMID: 32238512.
      View in: PubMed   Mentions:    Fields:    
    16. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial. Arthritis Res Ther. 2020 03 06; 22(1):43. Mease P, Husni ME, Kafka S, Chakravarty SD, Harrison DD, Lo KH, Xu S, Hsia EC, Kavanaugh A. PMID: 32143685.
      View in: PubMed   Mentions:    Fields:    
    17. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020 Jun; 82(6):1445-1486. Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani RN, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmets CA. PMID: 32119894.
      View in: PubMed   Mentions: 2     Fields:    
    18. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken). 2020 04; 72(4):461-488. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, Marder W, Guyatt G, Branch DW, Buyon J, Christopher-Stine L, Crow-Hercher R, Cush J, Druzin M, Kavanaugh A, Laskin CA, Plante L, Salmon J, Simard J, Somers EC, Steen V, Tedeschi SK, Vinet E, White CW, Yazdany J, Barbhaiya M, Bettendorf B, Eudy A, Jayatilleke A, Shah AA, Sullivan N, Tarter LL, Birru Talabi M, Turgunbaev M, Turner A, D'Anci KE. PMID: 32090466.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    19. Correlation of serum protein biomarkers with disease activity in psoriatic arthritis. Expert Rev Clin Immunol. 2020 Mar; 16(3):335-341. Boyd TA, Eastman PS, Huynh DH, Qureshi F, Sasso EH, Bolce R, Temple J, Hillman J, Boyle DL, Kavanaugh A. PMID: 32067517.
      View in: PubMed   Mentions:    Fields:    
    20. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020 04; 72(4):529-556. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, Marder W, Guyatt G, Branch DW, Buyon J, Christopher-Stine L, Crow-Hercher R, Cush J, Druzin M, Kavanaugh A, Laskin CA, Plante L, Salmon J, Simard J, Somers EC, Steen V, Tedeschi SK, Vinet E, White CW, Yazdany J, Barbhaiya M, Bettendorf B, Eudy A, Jayatilleke A, Shah AA, Sullivan N, Tarter LL, Birru Talabi M, Turgunbaev M, Turner A, D'Anci KE. PMID: 32090480.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    21. Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies. Rheumatol Int. 2020 May; 40(5):747-755. Koehm M, McIntosh MJ, Hofmann MW, Abraham V, Gabay C, Choy EH, Kavanaugh A, Burkhardt H, Behrens F. PMID: 32040761.
      View in: PubMed   Mentions:    Fields:    
    22. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2020 02 08; 395(10222):427-440. Ritchlin CT, Kavanaugh A, Merola JF, Schett G, Scher JU, Warren RB, Gottlieb AB, Assudani D, Bedford-Rice K, Coarse J, Ink B, McInnes IB. PMID: 32035552.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    23. Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. Arthritis Res Ther. 2020 02 03; 22(1):18. van der Heijde D, Gladman DD, Kavanaugh A, Mease PJ. PMID: 32014044.
      View in: PubMed   Mentions:    Fields:    
    24. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. RMD Open. 2020 02; 6(1). Helliwell PS, Gladman DD, Chakravarty SD, Kafka S, Karyekar CS, You Y, Campbell K, Sweet K, Kavanaugh A, Gensler LS. PMID: 32209721.
      View in: PubMed   Mentions:
    25. Psoriatic Arthritis: Newer and Older Therapies. Curr Rheumatol Rep. 2019 12 21; 21(12):75. Chao R, Kavanaugh A. PMID: 31865449.
      View in: PubMed   Mentions: 1     Fields:    
    26. Adiposity and physical activity as risk factors for developing psoriatic arthritis. Longitudinal data from the HUNT study. Arthritis Care Res (Hoboken). 2019 Dec 07. Thomsen RS, Nilsen TI, Haugeberg G, Gulati AM, Kavanaugh A, Hoff M. PMID: 31811695.
      View in: PubMed   Mentions: 1     Fields:    
    27. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol. 2020 Jan; 2(1):18-25. Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S. PMID: 31943974.
      View in: PubMed   Mentions:
    28. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020 Jan; 82(1):161-201. Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmets CA. PMID: 31703821.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    29. Bedside to bench: defining the immunopathogenesis of psoriatic arthritis. Nat Rev Rheumatol. 2019 11; 15(11):645-656. Bravo A, Kavanaugh A. PMID: 31485004.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. RMD Open. 2019; 5(2):e000990. McInnes IB, Chakravarty SD, Apaolaza I, Kafka S, Hsia EC, You Y, Kavanaugh A. PMID: 31565242.
      View in: PubMed   Mentions:
    31. Treat to Target in Psoriatic Arthritis. Rheum Dis Clin North Am. 2019 11; 45(4):505-517. Zhang AD, Kavanaugh A. PMID: 31564293.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019 Sep; 81(3):775-804. Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, Armstrong AW, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Leonardi CL, Lichten J, Mehta NN, Paller AS, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. PMID: 31351884.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    33. GRAPPA 2018 Project Report. J Rheumatol Suppl. 2019 Jun; 95:54-57. Goel N, FitzGerald O, Gladman DD, Helliwell PS, Kavanaugh A, Maksymowych WP, Mease PJ, Ritchlin CT, Coates LC. PMID: 31154406.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Arthritis Res Ther. 2019 05 28; 21(1):130. Jaworski J, Matucci-Cerinic M, Schulze-Koops H, Buch MH, Kucharz EJ, Allanore Y, Kavanaugh A, Young P, Babic G. PMID: 31138316.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    35. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Ann Rheum Dis. 2019 09; 78(9):1215-1219. Kavanaugh A, Gottlieb A, Morita A, Merola JF, Lin CY, Birt J, Shuler CL, Hufford MM, Thaçi D. PMID: 31113794.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    36. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Arthritis Res Ther. 2019 05 10; 21(1):118. Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ. PMID: 31077258.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    37. Pro- and anti-inflammatory eicosanoids in psoriatic arthritis. Metabolomics. 2019 04 19; 15(4):65. Coras R, Kavanaugh A, Boyd T, Huynh Q, Pedersen B, Armando AM, Dahlberg-Wright S, Marsal S, Jain M, Paravar T, Quehenberger O, Guma M. PMID: 31004236.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    38. Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate- or methotrexate-treated rheumatoid arthritis patients in OPTIMA. Clin Exp Rheumatol. 2019 Sep-Oct; 37(5):783-790. Skapenko A, Smolen JS, Kavanaugh A, Arora V, Kupper H, Schulze-Koops H. PMID: 30963994.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    39. Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials. J Rheumatol. 2019 11; 46(11):1458-1461. McInnes IB, Puig L, Gottlieb AB, Ritchlin CT, Song M, You Y, Kafka S, Morgan GJ, Rahman P, Kavanaugh A. PMID: 30936281.
      View in: PubMed   Mentions:    Fields:    
    40. Impact of High-Intensity Interval Training on Disease Activity and Disease in Patients With Psoriatic Arthritis: A Randomized Controlled Trial. Arthritis Care Res (Hoboken). 2019 04; 71(4):530-537. Thomsen RS, Nilsen TIL, Haugeberg G, Bye A, Kavanaugh A, Hoff M. PMID: 29882634.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    41. Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. J Rheumatol. 2019 09; 46(9):1089-1096. van der Heijde D, Gladman DD, FitzGerald O, Kavanaugh A, Graham D, Wang C, Fallon L. PMID: 30824647.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    42. Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial. J Rheumatol. 2019 06; 46(6):595-602. Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Noonan L, Hsia EC. PMID: 30770519.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    43. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019 Apr; 80(4):1073-1113. Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. PMID: 30772097.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    44. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr; 80(4):1029-1072. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA. PMID: 30772098.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    45. Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. J Rheumatol. 2019 05; 46(5):475-482. Ogdie A, Palmer JL, Greenberg J, Curtis JR, Harrold LR, Solomon DH, Kavanaugh A, Kremer JM, Mease PJ. PMID: 30647182.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    46. Choline metabolite, trimethylamine N-oxide (TMAO), is associated with inflammation in psoriatic arthritis. Clin Exp Rheumatol. 2019 May-Jun; 37(3):481-484. Coras R, Kavanaugh A, Boyd T, Huynh D, Lagerborg KA, Xu YJ, Rosenthal SB, Jain M, Guma M. PMID: 30620278.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    47. Techniques for improving the initial strength of the tibial tray-cement interface bond. Bone Joint J. 2019 Jan; 101-B(1_Supple_A):53-58. Billi F, Kavanaugh A, Schmalzried H, Schmalzried TP. PMID: 30648489.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    48. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. Arthritis Res Ther. 2018 12 07; 20(1):272. Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C. PMID: 30526678.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    49. Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks. Clin Exp Rheumatol. 2019 Jul-Aug; 37(4):566-574. Kavanaugh A, Marzo-Ortega H, Vender R, Wei CC, Birt J, Adams DH, Benichou O, Lin CY, Nash P. PMID: 30557128.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    50. Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. RMD Open. 2018; 4(2):e000757. Matucci-Cerinic M, Allanore Y, Kavanaugh A, Buch MH, Schulze-Koops H, Kucharz EJ, Woehling H, Babic G, Poetzl J, Davis A, Schwebig A. PMID: 30487998.
      View in: PubMed   Mentions:
    51. Effect of high-intensity interval training on cardiovascular disease risk factors and body composition in psoriatic arthritis: a randomised controlled trial. RMD Open. 2018; 4(2):e000729. Thomsen RS, Nilsen TIL, Haugeberg G, Bye A, Kavanaugh A, Hoff M. PMID: 30402265.
      View in: PubMed   Mentions:
    52. Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry. BMC Rheumatol. 2018; 2:29. Kavanaugh A, Papp K, Gottlieb AB, de Jong EMGJ, Chakravarty SD, Kafka S, Langholff W, Farahi K, Srivastava B, Scher JU. PMID: 30886979.
      View in: PubMed   Mentions:
    53. Golimumab in the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2018 11; 14(11):893-898. Love TJ, Kavanaugh A. PMID: 30221556.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    54. The role of golimumab in inflammatory arthritis. A review of the evidence. Ther Adv Musculoskelet Dis. 2018 Sep; 10(9):181-194. Tahir Z, Kavanaugh A. PMID: 30210584.
      View in: PubMed   Mentions:
    55. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open. 2018; 4(2):e000723. Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Mpofu S, Pricop L. PMID: 30167329.
      View in: PubMed   Mentions:
    56. Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. Ann Rheum Dis. 2018 11; 77(11):1566-1572. Smolen JS, van Vollenhoven RF, Florentinus S, Chen S, Suboticki JL, Kavanaugh A. PMID: 30076156.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    57. Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis. Arthritis Res Ther. 2018 08 03; 20(1):164. Narasimhan R, Coras R, Rosenthal SB, Sweeney SR, Lodi A, Tiziani S, Boyle D, Kavanaugh A, Guma M. PMID: 30075744.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    58. Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. Arthritis Res Ther. 2018 08 02; 20(1):160. Haugeberg G, Michelsen B, Tengesdal S, Hansen IJW, Diamantopoulos A, Kavanaugh A. PMID: 30071892.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    59. Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2018 10; 45(10):1389-1396. Mease PJ, Palmer JB, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, Karki C, Greenberg JD. PMID: 29961691.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    60. Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort. Arthritis Care Res (Hoboken). 2018 08; 70(8):1198-1205. Coates LC, Tillett W, Shaddick G, Pincus T, Kavanaugh A, Helliwell PS. PMID: 29112801.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    61. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open. 2018; 4(1):e000669. Gladman DD, Kavanaugh A, Gómez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ. PMID: 30018799.
      View in: PubMed   Mentions:
    62. Osteoporosis in psoriatic arthritis: a cross-sectional study of an outpatient clinic population. RMD Open. 2018; 4(1):e000631. Gulati AM, Michelsen B, Diamantopoulos A, Grandaunet B, Salvesen Ø, Kavanaugh A, Hoff M, Haugeberg G. PMID: 30018797.
      View in: PubMed   Mentions:
    63. Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis. Clin Rheumatol. 2018 Aug; 37(8):2275-2280. Kavanaugh A, Singh R, Karki C, Etzel CJ, Kremer JM, Greenberg JD, Griffith J. PMID: 29869112.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    64. Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. Rheumatol Ther. 2018 Dec; 5(2):341-353. Strand V, Kavanaugh A, Kivitz AJ, van der Heijde D, Kwok K, Akylbekova E, Soonasra A, Snyder M, Connell C, Bananis E, Smolen JS. PMID: 29761420.
      View in: PubMed   Mentions:
    65. Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. RMD Open. 2018; 4(1):e000638. Mease PJ, Karki C, Liu M, Kavanaugh A, Ritchlin CT, Huynh DH, Palmer JB, Greenberg JD. PMID: 29707232.
      View in: PubMed   Mentions:
    66. Radiographic Progression in Psoriatic Arthritis Achieving a Good Response to Treatment: Data Using Newer Composite Indices of Disease Activity. Arthritis Care Res (Hoboken). 2018 05; 70(5):797-800. Helliwell PS, Kavanaugh A. PMID: 28834259.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    67. Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study. RMD Open. 2018; 4(1):e000659. van der Heijde D, Braun J, Rudwaleit M, Purcaru O, Kavanaugh AF. PMID: 29670761.
      View in: PubMed   Mentions:
    68. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Res Ther. 2018 03 23; 20(1):57. Genovese M, Westhovens R, Meuleners L, Van der Aa A, Harrison P, Tasset C, Kavanaugh A. PMID: 29566740.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    69. Change in cardiovascular risk factors in patients who develop psoriatic arthritis: longitudinal data from the Nord-Trøndelag Health Study (HUNT). RMD Open. 2018; 4(1):e000630. Gulati AM, Salvesen Ø, Thomsen RS, Kavanaugh A, Semb AG, Rollefstad S, Haugeberg G, Hoff M. PMID: 29556420.
      View in: PubMed   Mentions:
    70. Rheumatoid arthritis. Nat Rev Dis Primers. 2018 02 08; 4:18001. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K. PMID: 29417936.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansPHPublic Health
    71. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. Arthritis Rheumatol. 2018 03; 70(3):345-355. Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS. PMID: 29193765.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    72. Risk of infantile hemangiomas in the offspring of women with autoimmune disease and the pathogenic implications of these lesions. Am J Med Genet A. 2018 03; 176(3):570-577. Smith CJF, Jones KL, Johnson DL, Bandoli G, Robinson LK, Kavanaugh A, Chambers CD. PMID: 29341431.
      View in: PubMed   Mentions:
    73. Three-dimensional ultrashort echo time cones (3D UTE-Cones) magnetic resonance imaging of entheses and tendons. Magn Reson Imaging. 2018 06; 49:4-9. Chen B, Zhao Y, Cheng X, Ma Y, Chang EY, Kavanaugh A, Liu S, Du J. PMID: 29309823.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    74. Rheumatoid arthritis: Do TNF inhibitors influence lymphoma development? Nat Rev Rheumatol. 2017 11 21; 13(12):697-698. Kavanaugh A. PMID: 29158571.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    75. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. Ann Rheum Dis. 2018 02; 77(2):289-292. Kavanaugh A, van Vollenhoven RF, Fleischmann R, Emery P, Sainsbury I, Florentinus S, Chen S, Guérette B, Kupper H, Smolen JS. PMID: 29146743.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    76. Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Arthritis Care Res (Hoboken). 2017 11; 69(11):1692-1699. Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Tran M, Greenberg JD. PMID: 28376239.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    77. Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study. Arthritis Rheumatol. 2017 11; 69(11):2151-2161. Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC. PMID: 28805045.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    78. Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. RMD Open. 2017; 3(2):e000445. Keystone EC, Breedveld FC, van der Heijde D, van Vollenhoven RF, Emery P, Smolen JS, Sainsbury I, Florentinus S, Kupper H, Chen K, Kavanaugh A. PMID: 29018564.
      View in: PubMed   Mentions:
    79. Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. RMD Open. 2017; 3(2):e000465. Burmester GR, Kaeley GS, Kavanaugh AF, Gabay C, MacCarter DK, Nash P, Takeuchi T, Goss SL, Rodila R, Chen K, Kupper H, Kalabic J. PMID: 28955494.
      View in: PubMed   Mentions:
    80. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. RMD Open. 2017; 3(2):e000496. Strand V, Michalska M, Birchwood C, Pei J, Tuckwell K, Finch R, Gabay C, Kavanaugh A, Jones G. PMID: 28955499.
      View in: PubMed   Mentions:
    81. Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout. Arthritis Res Ther. 2017 08 17; 19(1):191. Calabrese LH, Kavanaugh A, Yeo AE, Lipsky PE. PMID: 28818095.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    82. Achilles enthesitis defined by ultrasound is not associated with clinical enthesitis in patients with psoriatic arthritis. RMD Open. 2017; 3(2):e000486. Michelsen B, Diamantopoulos AP, Soldal DM, Hammer HB, Kavanaugh A, Haugeberg G. PMID: 28879054.
      View in: PubMed   Mentions:
    83. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. Rheumatology (Oxford). 2017 08 01; 56(8):1251-1253. Coates LC, Gossec L, Ramiro S, Mease P, van der Heijde D, Smolen JS, Ritchlin C, Kavanaugh A. PMID: 28077693.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    84. Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. RMD Open. 2017; 3(1):e000415. Mease PJ, Kavanaugh A, Coates LC, McInnes IB, Hojnik M, Zhang Y, Anderson JK, Dorr AP, Gladman DD. PMID: 29225916.
      View in: PubMed   Mentions:
    85. Bone mineral density in patients with psoriatic arthritis: data from the Nord-Trøndelag Health Study 3. RMD Open. 2017; 3(1):e000413. Gulati AM, Hoff M, Salvesen Ø, Dhainaut A, Semb AG, Kavanaugh A, Haugeberg G. PMID: 28955483.
      View in: PubMed   Mentions:
    86. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 01; 77(1):3-17. Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D. PMID: 28684559.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    87. Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry. Rheumatology (Oxford). 2017 07 01; 56(7):1095-1101. Kavanaugh A, Keystone E, Greenberg JD, Reed GW, Griffith JM, Friedman AW, Saunders KC, Ganguli A. PMID: 28340006.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    88. Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry. J Rheumatol. 2017 08; 44(8):1151-1158. Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Tran M, Greenberg JD. PMID: 28620063.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    89. Proceedings of the GRAPPA 2016 Retreat. J Rheumatol. 2017 05; 44(5):668-673. Jadon DR, Gladman DD, Mease PJ, FitzGerald O, Chandran V, Goel N, Rosen CF, Maksymowych WP, Ritchlin CT, Ogdie A, Coates LC, Cauli A, Soriano ER, Husni ME, Campbell W, Azevedo VF, Callis Duffin K, Armstrong AW, Gottlieb AB, Kavanaugh A, Garg A, Helliwell PS. PMID: 28461522.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    90. International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting. J Rheumatol. 2017 05; 44(5):684-685. Coates LC, Chandran V, Ogdie A, O'Sullivan D, Brooke M, Steinkoenig I, Mease PJ, Ritchlin CT, Kavanaugh A. PMID: 28461525.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    91. Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment. Birth Defects Res. 2017 Jul 03; 109(11):809-815. Smith CJF, Friedlander SF, Guma M, Kavanaugh A, Chambers CD. PMID: 28402073.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    92. Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study. Arthritis Care Res (Hoboken). 2017 03; 69(3):347-355. Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, Geusens P, Wang Z, Pricop L, Mpofu S. PMID: 27696786.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    93. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population. J Rheumatol. 2017 04; 44(4):431-436. Michelsen B, Diamantopoulos AP, Høiberg HK, Soldal DM, Kavanaugh A, Haugeberg G. PMID: 28148701.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    94. Magic angle effect plays a major role in both T1rho and T2 relaxation in articular cartilage. Osteoarthritis Cartilage. 2017 12; 25(12):2022-2030. Shao H, Pauli C, Li S, Ma Y, Tadros AS, Kavanaugh A, Chang EY, Tang G, Du J. PMID: 28161394.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    95. Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis. RMD Open. 2017; 3(1):e000395. Huynh DH, Boyd TA, Etzel CJ, Cox V, Kremer J, Mease P, Kavanaugh A. PMID: 28123783.
      View in: PubMed   Mentions:
    96. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017 Jun; 76(6):1009-1019. Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P. PMID: 27993828.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    97. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol. 2016 Dec; 12(12):743-750. Gossec L, Coates LC, de Wit M, Kavanaugh A, Ramiro S, Mease PJ, Ritchlin CT, van der Heijde D, Smolen JS. PMID: 27829672.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    98. Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2016 12; 68(12):1812-1822. Rahman P, Puig L, Gottlieb AB, Kavanaugh A, McInnes IB, Ritchlin C, Li S, Wang Y, Song M, Mendelsohn A, Han C. PMID: 27483458.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    99. Information technology in rheumatology. Clin Exp Rheumatol. 2016 Sep-Oct; 34(5 Suppl 101):1. Pincus T, Braun J, Kavanaugh A, Ravelli A, Smolen JS. PMID: 27762207.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    100. Adult Inflammatory Arthritides: What the Radiologist Should Know. Radiographics. 2016 Oct; 36(6):1849-1870. Chang EY, Chen KC, Huang BK, Kavanaugh A. PMID: 27726745.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    101. Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. J Clin Aesthet Dermatol. 2016 Sep; 9(9 Suppl 1):S5-S29. Martin G, Strober BE, Leonardi CL, Gelfand JM, Blauvelt A, Kavanaugh A, Stein Gold L, Berman B, Rosen T, Stockfleth E. PMID: 27800119.
      View in: PubMed   Mentions:
    102. Secukinumab for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2016 Oct; 12(10):1027-36. Baronaite Hansen R, Kavanaugh A. PMID: 27550397.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    103. Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. RMD Open. 2016; 2(2):e000289. Sweeney SR, Kavanaugh A, Lodi A, Wang B, Boyle D, Tiziani S, Guma M. PMID: 27651926.
      View in: PubMed   Mentions:
    104. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open. 2016; 2(2):e000262. Fleischmann RM, Huizinga TW, Kavanaugh AF, Wilkinson B, Kwok K, DeMasi R, van Vollenhoven RF. PMID: 27493790.
      View in: PubMed   Mentions:
    105. Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. J Rheumatol. 2016 09; 43(9):1713-7. Kavanaugh A, McInnes IB, Mease PJ, Hall S, Chinoy H, Kivitz AJ, Wang Z, Mpofu S. PMID: 27307536.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    106. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care Res (Hoboken). 2016 05; 68(5):667-72. de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, Cimmino MA, da Rocha Castelar Pinheiro G, Day R, Harrold LR, Helliwell P, Janssen M, Kerr G, Kavanaugh A, Khanna D, Khanna PP, Lin C, Louthrenoo W, McCarthy G, Vazquez-Mellado J, Mikuls TR, Neogi T, Ogdie A, Perez-Ruiz F, Schlesinger N, Ralph Schumacher H, Scirè CA, Singh JA, Sivera F, Slot O, Stamp LK, Tausche AK, Terkeltaub R, Uhlig T, van de Laar M, White D, Yamanaka H, Zeng X, Dalbeth N. PMID: 26414176.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    107. Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations. Arthritis Res Ther. 2016 Apr 26; 18:94. Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Kavanaugh A, Saunders KC, Shan Y, Spruill TM, Pappas DA, Greenberg JD. PMID: 27118040.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    108. Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate. Rheumatology (Oxford). 2016 08; 55(8):1458-65. Emery P, Smolen JS, Ganguli A, Meerwein S, Bao Y, Kupper H, Chen N, Kavanaugh A. PMID: 27114561.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    109. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheum Dis. 2016 Nov; 75(11):1984-1988. Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, You Y, Li S, Song M, Randazzo B, Rahman P, McInnes IB. PMID: 27098404.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    110. Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity. Ann Rheum Dis. 2016 Dec; 75(12):2108-2113. Michelsen B, Diamantopoulos AP, Hammer HB, Soldal DM, Kavanaugh A, Haugeberg G. PMID: 27091837.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    111. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016 05; 68(5):1060-71. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O'Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT. PMID: 26749174.
      View in: PubMed   Mentions: 121     Fields:    Translation:Humans
    112. Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Rheumatol Ther. 2016 Jun; 3(1):91-102. Kavanaugh A, Helliwell P, Ritchlin CT. PMID: 27747516.
      View in: PubMed   Mentions:
    113. US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Am J Clin Dermatol. 2016 Feb; 17(1):87-97. Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. PMID: 26718712.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    114. Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. Arthritis Care Res (Hoboken). 2016 Feb; 68(2):267-74. Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger GG, McInnes IB, Helliwell P, Coates LC, Xu S. PMID: 25779603.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    115. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016 Jan; 137(1):19-27. Her M, Kavanaugh A. PMID: 26768759.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimals
    116. Novel approaches to biological therapy for psoriatic arthritis. Expert Opin Biol Ther. 2016; 16(2):173-86. Boyd T, Kavanaugh A. PMID: 26572089.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    117. Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. Arthritis Care Res (Hoboken). 2015 Dec; 67(12):1739-49. Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, Li S, Wang Y, Mendelsohn AM, Song M, Zhu Y, Rahman P, McInnes IB. PMID: 26097039.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    118. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Oct; 75(10):1806-12. Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J, Sattar N. PMID: 26613768.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    119. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 Jan; 68(1):1-25. Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. PMID: 26545825.
      View in: PubMed   Mentions: 155     Fields:    Translation:Humans
    120. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016 Jan; 68(1):1-26. Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. PMID: 26545940.
      View in: PubMed   Mentions: 383     Fields:    Translation:Humans
    121. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study. J Rheumatol. 2015 Dec; 42(12):2238-46. Yoshida K, Radner H, Mjaavatten MD, Greenberg JD, Kavanaugh A, Kishimoto M, Matsui K, Okada M, Reed G, Saeki Y, Tohma S, Kremer J, Solomon DH. PMID: 26523025.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    122. Interleukin-17 inhibition in psoriatic arthritis. Clin Exp Rheumatol. 2015 Sep-Oct; 33(5 Suppl 93):S119-23. Boyd T, Kavanaugh A. PMID: 26471234.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    123. An overview of low disease activity and remission in psoriatic arthritis. Clin Exp Rheumatol. 2015 Sep-Oct; 33(5 Suppl 93):S51-4. Lubrano E, Perrotta FM, Kavanaugh A. PMID: 26470835.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    124. Trial design in psoriatic arthritis: what could be changed? Clin Exp Rheumatol. 2015 Jul-Aug; 33(4 Suppl 92):S15-8. Kavanaugh A, Boyd T. PMID: 26458015.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    125. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med. 2015 Oct; 373(14):1329-39. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S. PMID: 26422723.
      View in: PubMed   Mentions: 140     Fields:    Translation:HumansCTClinical Trials
    126. Clinical guidelines: Addressing comorbidities in systemic inflammatory disorders. Nat Rev Rheumatol. 2015 Dec; 11(12):689-91. Boyd T, Kavanaugh A. PMID: 26390846.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    127. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis Res Ther. 2015 Sep 10; 17:245. Smolen JS, van Vollenhoven R, Kavanaugh A, Strand V, Vencovsky J, Schiff M, Landewé R, Haraoui B, Arendt C, Mountian I, Carter D, van der Heijde D. PMID: 26353833.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    128. Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting. J Clin Aesthet Dermatol. 2015 Sep; 8(9 Suppl):S4-S26. Desai SR, Frieden IJ, Gelfand JM, High W, Kavanaugh A, Marghoob AA, Ozog DM, Rosen T, Stein Gold L, Strober B, Swanson N, Martin G. PMID: 26504503.
      View in: PubMed   Mentions:
    129. Novel Treatment Concepts in Psoriatic Arthritis. Rheum Dis Clin North Am. 2015 Nov; 41(4):739-54. Boyd T, Kavanaugh A. PMID: 26476230.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    130. Pregnancy: Data, Outcomes, and Treatment Paradigms in Rheumatology. J Rheumatol. 2015 Aug; 42(8):1357-8. Kavanaugh A, Cush JJ. PMID: 26233947.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    131. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. Rheumatology (Oxford). 2015 Dec; 54(12):2188-97. Furst DE, Kavanaugh A, Florentinus S, Kupper H, Karunaratne M, Birbara CA. PMID: 26199453.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    132. Psoriatic arthritis: latest treatments and their place in therapy. Ther Adv Chronic Dis. 2015 Jul; 6(4):194-203. Kang EJ, Kavanaugh A. PMID: 26137209.
      View in: PubMed   Mentions:
    133. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 Sep 19; 386(9999):1137-46. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S. PMID: 26135703.
      View in: PubMed   Mentions: 155     Fields:    Translation:HumansCTClinical Trials
    134. Salivary Gland Ultrasonography as a Diagnostic Tool for Secondary Sjögren Syndrome in Rheumatoid Arthritis. J Rheumatol. 2015 Jul; 42(7):1119-22. Das S, Huynh D, Yang H, Ceponis A, Kavanaugh A. PMID: 25934827.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    135. Advances in use of immunomodulatory agents--a rheumatology perspective. Nat Rev Gastroenterol Hepatol. 2015 Jun; 12(6):363-8. Her M, Kavanaugh A. PMID: 25895821.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    136. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Dermatol Venereol. 2015 Oct; 29(10):2002-10. van de Kerkhof PC, Reich K, Kavanaugh A, Bachelez H, Barker J, Girolomoni G, Langley RG, Paul CF, Puig L, Lebwohl MG. PMID: 25885420.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    137. A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS One. 2015; 10(4):e0123582. Michelsen B, Fiane R, Diamantopoulos AP, Soldal DM, Hansen IJ, Sokka T, Kavanaugh A, Haugeberg G. PMID: 25853482.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    138. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations. J Rheumatol. 2015 Jun; 42(6):952-9. Van den Bosch F, Kavanaugh A, Kron M, Kupper H, Mease PJ. PMID: 25834212.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    139. Drug safety evaluation of apremilast for treating psoriatic arthritis. Expert Opin Drug Saf. 2015 Jun; 14(6):979-85. Busa S, Kavanaugh A. PMID: 25827658.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    140. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study. Ann Rheum Dis. 2016 May; 75(5):819-24. Gulati AM, Semb AG, Rollefstad S, Romundstad PR, Kavanaugh A, Gulati S, Haugeberg G, Hoff M. PMID: 25814652.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    141. Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res (Hoboken). 2015 Mar; 67(3):313-25. Kavanaugh A, Cush JJ, Ahmed MS, Bermas BL, Chakravarty E, Chambers C, Clowse M, Curtis JR, Dao K, Hankins GD, Koren G, Kim SC, Lapteva L, Mahadevan U, Moore T, Nolan M, Ren Z, Sammaritano LR, Seymour S, Weisman MH. PMID: 25385050.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimals
    142. Certolizumab pegol for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2015 Mar; 11(3):307-18. Hansen RB, Kavanaugh A. PMID: 25651776.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    143. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015 Mar; 42(3):479-88. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E, Hall S. PMID: 25593233.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    144. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. Ann Rheum Dis. 2015 Jun; 74(6):1150-5. Kavanaugh A, Lee SJ, Curtis JR, Greenberg JD, Kremer JM, Soto L, Etzel CJ, Cox V, Yoshida K, Reed GW, Solomon DH. PMID: 25471471.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    145. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatol. 2014 Dec; 66(12):3255-64. Weinblatt ME, Genovese MC, Ho M, Hollis S, Rosiak-Jedrychowicz K, Kavanaugh A, Millson DS, Leon G, Wang M, van der Heijde D. PMID: 25223724.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    146. Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res (Hoboken). 2014 Dec; 66(12):1759-66. Helliwell P, Coates L, Chandran V, Gladman D, de Wit M, FitzGerald O, Kavanaugh A, Strand V, Mease PJ, Boehncke WH, Langley RG, Lubrano E, Maccarone M, Schulze-Koops H, Miceli-Richard C, Queiro R. PMID: 25047391.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    147. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015 Jun; 74(6):1311-6. Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, Shurmur R, Singhal AK, Wei N, Rosengren S, Kaplan I, Krishnaswami S, Luo Z, Bradley J, Firestein GS. PMID: 25398374.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCellsCTClinical Trials
    148. Treatments for nail psoriasis: a systematic review by the GRAPPA Nail Psoriasis Work Group. J Rheumatol. 2014 Nov; 41(11):2306-14. Armstrong AW, Tuong W, Love TJ, Carneiro S, Grynszpan R, Lee SS, Kavanaugh A. PMID: 25362716.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    149. Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA. J Rheumatol. 2014 Nov; 41(11):2273-6. Coates LC, Kavanaugh A, Ritchlin CT. PMID: 25362710.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    150. Optimisation of assessment for rheumatic diseases in clinical trials, observational studies and routine clinical care. Clin Exp Rheumatol. 2014 Sep-Oct; 32(5 Suppl 85):S-1. Pincus T, Braun J, Kavanaugh A, Smolen JS. PMID: 25365080.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    151. Sustained Improvements in Workplace and Household Productivity and Social Participation With Certolizumab Pegol Over 96 Weeks in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. Value Health. 2014 Nov; 17(7):A387. van dH, Braun J, Rudwaleit M, Purcaru O, Kavanaugh A. PMID: 27200883.
      View in: PubMed   Mentions:    Fields:    
    152. Sustained Improvements in Workplace and Household Productivity and Social Participation With Certolizumab Pegol Over 96 Weeks in Patients With Psoriatic Arthritis. Value Health. 2014 Nov; 17(7):A387-8. Kavanaugh A, Gladman D, van dH, Purcaru O, Mease PJ. PMID: 27200879.
      View in: PubMed   Mentions: 1     Fields:    
    153. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-a antagonist. J Rheumatol. 2014 Nov; 41(11):2120-8. Genovese MC, van der Heijde DM, Keystone EC, Spindler AJ, Benhamou C, Kavanaugh A, Fudman E, Lampl K, O'Brien C, Duffield EL, Poiley J, Weinblatt ME. PMID: 25225285.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    154. Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis? Ann Rheum Dis. 2015 Dec; 74(12):2165-74. Emery P, Kavanaugh A, Bao Y, Ganguli A, Mulani P. PMID: 25139667.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    155. Psoriatic arthritis: current therapy and future approaches. Rheumatology (Oxford). 2015 Jan; 54(1):20-8. Huynh D, Kavanaugh A. PMID: 25125588.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    156. Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example. Ann Rheum Dis. 2014 Oct; 73(10):1755-60. Landewé RB, Smolen JS, Weinblatt ME, Emery P, Dougados M, Fleischmann R, Aletaha D, Kavanaugh A, van der Heijde D. PMID: 25114058.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    157. A review of disease activity measures for psoriatic arthritis: what is the best approach? Expert Rev Clin Immunol. 2014 Sep; 10(9):1241-54. Her M, Kavanaugh A. PMID: 25088300.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    158. Concepts of pathogenesis and emerging treatments for inflammatory arthritis. Best Pract Res Clin Rheumatol. 2014 Aug; 28(4):537-8. van Laar JM, Kavanaugh A. PMID: 25481547.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    159. Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. Ann Rheum Dis. 2015 Jan; 74(1):44-51. Kavanaugh A, Gladman D, van der Heijde D, Purcaru O, Mease P. PMID: 24942382.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    160. GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting. J Rheumatol. 2014 Jun; 41(6):1237-9. Coates LC, Ritchlin CT, Kavanaugh AF. PMID: 24882861.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    161. Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. Arthritis Care Res (Hoboken). 2014 May; 66(5):749-56. Helliwell PS, Kavanaugh A. PMID: 24127416.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    162. Editorial: pregnancy and rheumatoid arthritis - do not let the perfect become the enemy of the good. Curr Opin Rheumatol. 2014 May; 26(3):299-301. Cush JJ, Kavanaugh A. PMID: 24667288.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    163. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther. 2014; 16(2):R90. Dennis G, Holweg CT, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA, Haverty PM, Gilbert H, Lin WY, Diehl L, Fischer S, Song A, Musselman D, Klearman M, Gabay C, Kavanaugh A, Endres J, Fox DA, Martin F, Townsend MJ. PMID: 25167216.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCellsCTClinical Trials
    164. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014 Sep; 73(9):1689-94. Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, van der Heijde D, Zhou Y, Lu J, Leu JH, Goldstein N, Beutler A. PMID: 24748630.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    165. Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis. Rheumatology (Oxford). 2014 Oct; 53(10):1742-51. Kavanaugh A, Wells AF. PMID: 24729402.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    166. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014 Mar 04; 16(2):R60. Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, Becker MA. PMID: 24588936.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    167. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014 Jun; 73(6):1020-6. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C, Hough D, Stevens RM, Schett G. PMID: 24595547.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCTClinical Trials
    168. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014 May; 70(5):871-81.e1-30. Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, Paul CF, Puig L, Reich K, van de Kerkhof PC. PMID: 24576585.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    169. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014 Jun; 73(6):1000-6. Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, Wang Y, Noonan L, Brodmerkel C, Song M, Mendelsohn AM, McInnes IB. PMID: 24553909.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    170. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014 Feb; 141(2):133-42. Kirkham BW, Kavanaugh A, Reich K. PMID: 23819583.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansAnimalsCells
    171. Utility of the ultrasound examination of the hand and wrist joints in the management of established rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Feb; 66(2):236-44. Ceponis A, Onishi M, Bluestein HG, Kalunian K, Townsend J, Kavanaugh A. PMID: 23983173.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    172. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014 Jun; 73(6):990-9. Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB. PMID: 24482301.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansCTClinical Trials
    173. Novel treatments with small molecules in psoriatic arthritis. Curr Rheumatol Rep. 2014; 16(9):443. Hansen RB, Kavanaugh A. PMID: 25027606.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    174. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. 2015 Mar; 74(3):538-46. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A. PMID: 24344160.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    175. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study. J Rheumatol. 2014 Feb; 41(2):235-43. Keystone EC, Haraoui B, Guérette B, Mozaffarian N, Liu S, Kavanaugh A. PMID: 24293583.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    176. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J Rheumatol. 2014 Jan; 41(1):5-14. Keystone EC, Breedveld FC, van der Heijde D, Landewé R, Florentinus S, Arulmani U, Liu S, Kupper H, Kavanaugh A. PMID: 24241487.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    177. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2014 Jan 25; 383(9914):321-32. Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, Guérette B, Kupper H, Redden L, Arora V, Kavanaugh A. PMID: 24168956.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    178. Response to: 'Biologic discontinuation studies: a systematic review of methods' by van der Maas et al. Ann Rheum Dis. 2014 Jan; 73(1):e5. Yoshida K, Sung YK, Kavanaugh A, Bae SC, Weinblatt ME, Kishimoto M, Matsui K, Tohma S, Solomon DH. PMID: 24152418.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    179. Possible discontinuation of therapies in inflammatory rheumatic diseases - as with initiation of therapies, a shared decision between patient and rheumatologist. Clin Exp Rheumatol. 2013 Jul-Aug; 31(4 Suppl 78):S1-3. Pincus T, Braun J, Kavanaugh A, Smolen JS. PMID: 24129127.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    180. The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials. Clin Exp Rheumatol. 2013 Jul-Aug; 31(4 Suppl 78):S19-21. Kavanaugh A, Smolen JS. PMID: 24129131.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    181. Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities. Clin Exp Rheumatol. 2013 Jul-Aug; 31(4 Suppl 78):S28-32. Yoshida K, Radner H, Kavanaugh A, Sung YK, Bae SC, Kishimoto M, Matsui K, Okada M, Tohma S, Weinblatt ME, Solomon DH. PMID: 24129133.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    182. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken). 2013 Oct; 65(10):1666-73. Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, Mack M, Tandon N, Han C, Mease P. PMID: 23666608.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    183. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1042-50.e2. Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB, Sandborn WJ. PMID: 24036054.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansPHPublic Health
    184. Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting. J Clin Aesthet Dermatol. 2013 Sep; 6(9 Suppl):S2-S20. Blauvelt A, Brown M, Gordon KB, Kavanaugh A, Leonardi CT, Stockfleth E, Strober B, Swanson NA, Martin G. PMID: 24167640.
      View in: PubMed   Mentions:
    185. Adverse effects of golimumab in the treatment of rheumatologic diseases. Expert Opin Drug Saf. 2014 Jan; 13(1):103-12. Yang H, Kavanaugh A. PMID: 23984970.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    186. Prevalence and incidence rates of psoriatic arthritis in central Norway: data from the Nord-Trøndelag health study (HUNT). Ann Rheum Dis. 2015 Jan; 74(1):60-4. Hoff M, Gulati AM, Romundstad PR, Kavanaugh A, Haugeberg G. PMID: 23962458.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    187. Tocilizumab versus adalimumab for rheumatoid arthritis - Authors' reply. Lancet. 2013 Aug 03; 382(9890):395. Gabay C, Kavanaugh A. PMID: 23911377.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    188. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford). 2013 Oct; 52(10):1845-55. Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK. PMID: 23838027.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    189. Psoriatic arthritis: current therapy and future directions. Expert Opin Pharmacother. 2013 Sep; 14(13):1755-64. Huynh D, Kavanaugh A. PMID: 23815157.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    190. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. J Rheumatol. 2013 Sep; 40(9):1487-97. Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guérette B, Mozaffarian N. PMID: 23818718.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    191. Treatment of spondyloarthropathy: the potential for agents other than TNF inhibitors. Curr Opin Rheumatol. 2013 Jul; 25(4):455-9. Her M, Kavanaugh A. PMID: 23680779.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    192. Hand bone loss in patients with psoriatic arthritis: posthoc analysis of IMPACT II data comparing infliximab and placebo. J Rheumatol. 2013 Aug; 40(8):1344-8. Hoff M, Kavanaugh A, Haugeberg G. PMID: 23772084.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    193. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013 Aug 31; 382(9894):780-9. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK. PMID: 23769296.
      View in: PubMed   Mentions: 153     Fields:    Translation:HumansCTClinical Trials
    194. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014 Jan; 73(1):6-16. Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Schoels M, Sieper J, Wit Md, Baraliakos X, Betteridge N, Burgos-Vargas R, Collantes-Estevez E, Deodhar A, Elewaut D, Gossec L, Jongkees M, Maccarone M, Redlich K, van den Bosch F, Wei JC, Winthrop K, van der Heijde D. PMID: 23749611.
      View in: PubMed   Mentions: 94     Fields:    Translation:Humans
    195. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014 Jan; 73(1):238-42. Schoels MM, Braun J, Dougados M, Emery P, Fitzgerald O, Kavanaugh A, Kvien TK, Landewé R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Sieper J, Smolen JS, Wit Md, van der Heijde D. PMID: 23740234.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    196. Proceedings of the 2013 Rheumatology Winter Clinical Symposia. Semin Arthritis Rheum. 2013 Jun; 42(6):667-73. Kavanaugh A, Fleischmann R, Bergman MJ, Ruderman E, Troum O, Wells AF, Martin G, Calabrese LH, Gibofsky A, Strand V, Cush JJ. PMID: 23731828.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    197. Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis. 2014 Mar; 73(3):595-9. Yoshida K, Sung YK, Kavanaugh A, Bae SC, Weinblatt ME, Kishimoto M, Matsui K, Tohma S, Solomon DH. PMID: 23723316.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    198. Documentation of off-label use of biologics in Rheumatoid Arthritis. Ann Rheum Dis. 2013 Apr; 72 Suppl 2:ii35-51. Furst DE, Fleischman R, Kalden J, Kavanaugh A, Sieper J, Mease P, Smolen J, Breedveld F. PMID: 23532442.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    199. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis. 2013 Apr; 72 Suppl 2:ii2-34. Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Rubbert-Roth A, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop KL. PMID: 23532441.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    200. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013 May 04; 381(9877):1541-50. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A. PMID: 23515142.
      View in: PubMed   Mentions: 139     Fields:    Translation:HumansCTClinical Trials
    201. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol. 2013 Mar; 9(3):154-63. Choy EH, Kavanaugh AF, Jones SA. PMID: 23419427.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    202. A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. J Rheumatol. 2013 Apr; 40(4):498-505. Prowse RL, Dalbeth N, Kavanaugh A, Adebajo AO, Gaffo AL, Terkeltaub R, Mandell BF, Suryana BP, Goldenstein-Schainberg C, Diaz-Torne C, Khanna D, Lioté F, Mccarthy G, Kerr GS, Yamanaka H, Janssens H, Baraf HF, Chen JH, Vazquez-Mellado J, Harrold LR, Stamp LK, Van De Laar MA, Janssen M, Doherty M, Boers M, Edwards NL, Gow P, Chapman P, Khanna P, Helliwell PS, Grainger R, Schumacher HR, Neogi T, Jansen TL, Louthrenoo W, Sivera F, Taylor WJ, Alten R. PMID: 23418379.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    203. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2013 Apr; 40(4):369-78. Weinblatt ME, Kavanaugh A, Genovese MC, Jones DA, Musser TK, Grossbard EB, Magilavy DB. PMID: 23378467.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    204. Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study). Clin Exp Rheumatol. 2013 May-Jun; 31(3):358-64. Yazici Y, Curtis JR, Ince A, Baraf HS, Lepley DM, Devenport JN, Kavanaugh A. PMID: 23305631.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    205. Treat-to-target in rheumatoid arthritis: clinical and pharmacoeconomic considerations. Introduction. Clin Exp Rheumatol. 2012 Jul-Aug; 30(4 Suppl 73):S1. Turchetti G, Smolen JS, Kavanaugh A, Braun J, Pincus T, Bombardieri S. PMID: 23168235.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    206. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis. 2013 Nov; 72(11):1777-85. Kavanaugh A, McInnes IB, Mease PJ, Krueger GG, Gladman DD, van der Heijde D, Mudivarthy S, Xu W, Mack M, Xu Z, Beutler A. PMID: 23161902.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    207. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis. Clin Exp Rheumatol. 2012 Jul-Aug; 30(4 Suppl 73):S107-11. Her M, Kavanaugh A. PMID: 23078839.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    208. Psoriatic arthritis: treat-to-target. Clin Exp Rheumatol. 2012 Jul-Aug; 30(4 Suppl 73):S123-5. Kavanaugh A. PMID: 23078992.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    209. Methodological aspects and the interpretation of clinical trial data: lessons from the TEAR trial. Rheumatology (Oxford). 2013 Mar; 52(3):409-10. Fleischmann R, Kavanaugh A, Smolen J. PMID: 23070312.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    210. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis. 2013 Jan; 72(1):83-8. Wagner CL, Visvanathan S, Elashoff M, McInnes IB, Mease PJ, Krueger GG, Murphy FT, Papp K, Gomez-Reino JJ, Mack M, Beutler A, Gladman D, Kavanaugh A. PMID: 22975755.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    211. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012 Aug; 64(8):2504-17. Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, Gómez-Reino J, Papp K, Baratelle A, Xu W, Mudivarthy S, Mack M, Rahman MU, Xu Z, Zrubek J, Beutler A. PMID: 22378566.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    212. Assessment of psoriatic nail disease activity by rheumatologists: comment on the article by Lubrano et al. Arthritis Care Res (Hoboken). 2012 Aug; 64(8):1269; author reply 1269-70. Kavanaugh A. PMID: 22623218.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    213. Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs. Rheumatology (Oxford). 2012 Jul; 51 Suppl 5:v12-21. Pavelka K, Kavanaugh AF, Rubbert-Roth A, Ferraccioli G. PMID: 22718922.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    214. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL). J Rheumatol Suppl. 2012 Jul; 89:90-3. Kavanaugh A, Mease P. PMID: 22751603.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    215. Use of the 28-joint count yields significantly higher concordance between different examiners than the 66/68-joint count. J Rheumatol. 2012 Jul; 39(7):1334-40. Grunke M, Witt MN, Ronneberger M, Schnez A, Laubender RP, Engelbrecht M, Kavanaugh A, Schulze-Koops H. PMID: 22660799.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    216. Proceedings of the 2012 Rheumatology Winter Clinical Symposia. Semin Arthritis Rheum. 2012 Jun; 41(6):923-6. Kavanaugh A, Martin G, Cush JJ, Bergman MJ, Fleischmann R, Troum OM, Strand V, Ruderman EM, Wells AF. PMID: 22617482.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    217. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013 Jan; 72(1):64-71. Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, Santra S, Smolen JS. PMID: 22562973.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    218. Patient-reported outcomes in rheumatoid arthritis. Curr Opin Rheumatol. 2012 May; 24(3):327-34. Her M, Kavanaugh A. PMID: 22410543.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    219. Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year. Arthritis Care Res (Hoboken). 2012 May; 64(5):658-67. Curtis JR, Luijtens K, Kavanaugh A. PMID: 22231904.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    220. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 May; 64(5):625-39. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. PMID: 22473917.
      View in: PubMed   Mentions: 467     Fields:    Translation:Humans
    221. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012 Apr; 71 Suppl 2:i2-45. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K. PMID: 22460137.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    222. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. Dermatol Ther (Heidelb). 2012 Dec; 2(1):2. Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. PMID: 23205325.
      View in: PubMed   Mentions:
    223. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatol Ther (Heidelb). 2012 Dec; 2(1):1. Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. PMID: 23205324.
      View in: PubMed   Mentions:
    224. Patient assessments of skin, joint, and nail disease activity in psoriatic arthritis. J Rheumatol. 2012 Mar; 39(3):653; author reply 654. Kavanaugh A, Catalan T, Cassell S. PMID: 22383354.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    225. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012 Jan; 148(1):95-102. Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF. PMID: 22250239.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    226. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum. 2012 Jan; 64(1):21-32. Solomon DH, Mercer E, Kavanaugh A. PMID: 21898354.
      View in: PubMed   Mentions: 13     Fields:    
    227. Working at arthritis. Rheumatology (Oxford). 2012 Feb; 51(2):201-3. Short P, Jones AC, Walker D, Kavanaugh A, Moots RJ. PMID: 22179726.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    228. CXCL13 as a marker for outcome of rheumatoid arthritis: comment on the article by Meeuwisse et al. Arthritis Rheum. 2011 Nov; 63(11):3646-7. Rosengren S, Kalunian KC, Kavanaugh A, Boyle DL. PMID: 21834069.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    229. Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. Ann Rheum Dis. 2012 Feb; 71(2):206-12. Curtis JR, Yang S, Chen L, Park GS, Bitman B, Wang B, Navarro-Millan I, Kavanaugh A. PMID: 21998118.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    230. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012 Jan; 71(1):4-12. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Cañete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P. PMID: 21953336.
      View in: PubMed   Mentions: 107     Fields:    Translation:Humans
    231. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012 Feb; 71(2):198-205. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, Kavanaugh A. PMID: 21949007.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    232. Biologic modulators in allergic and autoinflammatory diseases. Curr Opin Allergy Clin Immunol. 2011 Aug; 11(4):355-60. Broderick L, Tourangeau LM, Kavanaugh A, Wasserman SI. PMID: 21659854.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    233. Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease. Am J Med. 2011 Apr; 124(4 Suppl):e1-18. Kavanaugh AF, Mayer LF, Cush JJ, Hanauer SB. PMID: 21531240.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    234. Proceedings of the 2011 Rheumatology Winter Clinical Symposia--Arthur Kavanaugh, MD and John J. Cush, MD (proceedings editors) [course directors: Arthur Kavanaugh, MD, George Martin, MD]. Semin Arthritis Rheum. 2011 Apr; 40(5):479-81. Kavanaugh A, Cush JJ. PMID: 21444001.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    235. Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis. Exp Cell Res. 2011 May 15; 317(9):1286-92. Mircic M, Kavanaugh A. PMID: 21439276.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    236. The role of monoclonal antibodies in the treatment of severe asthma. Ther Adv Respir Dis. 2011 Jun; 5(3):183-94. Tourangeau LM, Kavanaugh A, Wasserman SI. PMID: 21393345.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    237. Minimally important differences of the gout impact scale in a randomized controlled trial. Rheumatology (Oxford). 2011 Jul; 50(7):1331-6. Khanna D, Sarkin AJ, Khanna PP, Shieh MM, Kavanaugh AF, Terkeltaub RA, Lee SJ, Singh JA, Hirsch JD. PMID: 21372003.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    238. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis. 2011 Mar; 70 Suppl 1:i2-36. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K. PMID: 21339216.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    239. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. BMC Musculoskelet Disord. 2011 Feb 27; 12:54. Hoff M, Kvien TK, Kälvesten J, Elden A, Kavanaugh A, Haugeberg G. PMID: 21352592.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    240. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis. J Rheumatol. 2011 May; 38(5):855-62. Keystone EC, Kavanaugh A, Weinblatt ME, Patra K, Pangan AL. PMID: 21285171.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    241. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011 Feb; 63(2):337-45. Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, O'Brien M, Grossbard EB, Magilavy DB. PMID: 21279990.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCTClinical Trials
    242. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford). 2011 Mar; 50(3):603-10. Rosengren S, Wei N, Kalunian KC, Kavanaugh A, Boyle DL. PMID: 21098574.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    243. Rheumatology and work. Rheumatology (Oxford). 2010 Nov; 49(11):2007-9. Jones AC, Kavanaugh AF, Walker DJ. PMID: 20947529.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    244. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol. 2010 Sep-Oct; 28(5 Suppl 61):S132-7. Ceponis A, Kavanaugh A. PMID: 21044447.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    245. A pilot study of rituximab in immune-mediated inner ear disease. Audiol Neurootol. 2011; 16(4):214-21. Cohen S, Roland P, Shoup A, Lowenstein M, Silverstein H, Kavanaugh A, Harris J. PMID: 20980741.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    246. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Curr Med Res Opin. 2010 Oct; 26(10):2385-92. Kavanaugh A, Menter A, Mendelsohn A, Shen YK, Lee S, Gottlieb AB. PMID: 20831455.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    247. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol. 2010 Nov; 37(11):2237-46. van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewé R, Patra K, Pangan AL. PMID: 20889601.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    248. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010 Sep 30; 363(14):1303-12. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. PMID: 20879879.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansCTClinical Trials
    249. Health care utilization in patients with gout. Semin Arthritis Rheum. 2011 Jun; 40(6):501-11. Singh JA, Sarkin A, Shieh M, Khanna D, Terkeltaub R, Lee SJ, Kavanaugh A, Hirsch JD. PMID: 20828793.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    250. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum. 2010 Sep; 62(9):2582-91. Neogi T, Aletaha D, Silman AJ, Naden RL, Felson DT, Aggarwal R, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Khanna D, Kvien TK, Laing T, Liao K, Mease P, Ménard HA, Moreland LW, Nair R, Pincus T, Ringold S, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. PMID: 20872596.
      View in: PubMed   Mentions: 67     Fields:    Translation:Humans
    251. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep; 62(9):2569-81. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. PMID: 20872595.
      View in: PubMed   Mentions: 1371     Fields:    Translation:Humans
    252. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep; 69(9):1580-8. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. PMID: 20699241.
      View in: PubMed   Mentions: 661     Fields:    Translation:Humans
    253. Rheumatoid arthritis: Guidelines for RA therapy-avoiding hamartia. Nat Rev Rheumatol. 2010 Sep; 6(9):505-6. Kavanaugh A. PMID: 20808307.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    254. Predictors of doctor-rated and patient-rated gout severity: gout impact scales improve assessment. J Eval Clin Pract. 2010 Dec; 16(6):1244-7. Sarkin AJ, Levack AE, Shieh MM, Kavanaugh AF, Khanna D, Singh JA, Terkeltaub RA, Lee SJ, Hirsch JD. PMID: 20722884.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    255. Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res. 2010 Jul-Aug; 38(4):1213-24. Taylor P, Manger B, Alvaro-Gracia J, Johnstone R, Gomez-Reino J, Eberhardt E, Wolfe F, Schwartzman S, Furfaro N, Kavanaugh A. PMID: 20925993.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    256. Biologic agents in rheumatology: act II. Clin Exp Rheumatol. 2010 May-Jun; 28(3 Suppl 59):S2-4. Kavanaugh A. PMID: 20576218.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    257. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010 Aug; 69(8):1441-7. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. PMID: 20525844.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    258. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010 Sep; 69(9):1612-7. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed G, Calabrese L, Hooper M, Baumgartner S, Furst DE. PMID: 20448284.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    259. Treatment of psoriatic arthritis with biological agents. Semin Cutan Med Surg. 2010 Mar; 29(1):56-62. Ceponis A, Kavanaugh A. PMID: 20430309.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    260. Gout disease-specific quality of life and the association with gout characteristics. Patient Relat Outcome Meas. 2010 Mar 01; 2010:1-8. Hirsch JD, Terkeltaub R, Khanna D, Singh J, Sarkin A, Shieh M, Kavanaugh A, Lee SJ. PMID: 21686040.
      View in: PubMed   Mentions:
    261. Is a 12-week trial sufficient to evaluate clinical responses to etanercept or MTX treatment in early RA? Rheumatology (Oxford). 2010 Jun; 49(6):1201-3. Kavanaugh A, Keystone E, Feng J, Hooper M. PMID: 20181672.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    262. Patient-derived joint counts are a potential alternative for determining Disease Activity Score. J Rheumatol. 2010 May; 37(5):1035-41. Kavanaugh A, Lee SJ, Weng HH, Chon Y, Huang XY, Lin SL. PMID: 20156946.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    263. Standardization of joint examination technique leads to a significant decrease in variability among different examiners. J Rheumatol. 2010 Apr; 37(4):860-4. Grunke M, Antoni CE, Kavanaugh A, Hildebrand V, Dechant C, Schett G, Manger B, Ronneberger M. PMID: 20156953.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    264. Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008. J Rheumatol. 2010 Feb; 37(2):462-7. Ritchlin CT, Qureshi AA, de Vlam K, Pitzalis C, Helliwell PS, Mease PJ, Gladman DD, Krueger GG, Kavanaugh AF, Fitzgerald O. PMID: 20147482.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    265. Composite measures in psoriatic arthritis: GRAPPA 2008. J Rheumatol. 2010 Feb; 37(2):453-61. Gladman DD, Landewé R, McHugh NJ, Fitzgerald O, Thaci D, Coates L, Mease PJ, Qureshi AA, Krueger GG, Ritchlin CT, Kavanaugh AF, Garg A. PMID: 20147481.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    266. Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008. J Rheumatol. 2010 Feb; 37(2):448-52. Coates LC, McGonagle DM, Hodgson R, Gisondi P, Kavanaugh AF, Qureshi AA, Fitzgerald O, Mease PJ, Garg A, Rosen CF, Ridley D, Gladman DD, Krueger GG, Ritchlin CT, Helliwell PS. PMID: 20147480.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    267. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis. 2010 Jan; 69(1):43-7. Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg JD, Kavanaugh A, Reed G, Strand V, Kremer JM. PMID: 19147616.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    268. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis. 2010 Jan; 69 Suppl 1:i2-29. Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dörner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, Winthrop K. PMID: 19995740.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    269. Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins. J Allergy Clin Immunol. 2010 Feb; 125(2 Suppl 2):S314-23. Lee SJ, Chinen J, Kavanaugh A. PMID: 20036416.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    270. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum. 2009 Nov 15; 61(11):1592-600. Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, Strand V, van Vollenhoven RF. PMID: 19877104.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    271. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther. 2009; 11(6):R170. Strand V, Mease P, Burmester GR, Nikaï E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A. PMID: 19909548.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    272. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum. 2009 Nov; 60(11):3207-16. Koffeman EC, Genovese M, Amox D, Keogh E, Santana E, Matteson EL, Kavanaugh A, Molitor JA, Schiff MH, Posever JO, Bathon JM, Kivitz AJ, Samodal R, Belardi F, Dennehey C, van den Broek T, van Wijk F, Zhang X, Zieseniss P, Le T, Prakken BA, Cutter GC, Albani S. PMID: 19877047.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCellsCTClinical Trials
    273. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum. 2009 Sep 15; 61(9):1235-42. Chandran V, Gottlieb A, Cook RJ, Duffin KC, Garg A, Helliwell P, Kavanaugh A, Krueger GG, Langley RG, Lynde C, McHugh N, Mease P, Olivieri I, Rahman P, Rosen CF, Salvarani C, Thaci D, Toloza SM, Wong MY, Zhou QM, Gladman DD. PMID: 19714610.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    274. Treatment disparity related to race/ethnicity and education in rheumatoid arthritis patients: comment on the article by Constantinescu et al. Arthritis Rheum. 2009 Aug 15; 61(8):1141-2. Lee SJ, Kremer J, Kavanaugh A. PMID: 19644891.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    275. The efficacy of ustekinumab on the articular and dermatologic manifestations of psoriatic arthritis. Curr Rheumatol Rep. 2009 Aug; 11(4):233-4. Kavanaugh A. PMID: 19691924.
      View in: PubMed   Mentions: 1     Fields:    
    276. Therapy: Guidelines in rheumatology: quo vadis? Nat Rev Rheumatol. 2009 Aug; 5(8):423-4. Kavanaugh A. PMID: 19648942.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    277. A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol. 2009 Jul; 61(1 Suppl 1):S1-S46. Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. PMID: 19527820.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    278. Infection prophylaxis in antirheumatic therapy: emphasis on vaccination. Curr Opin Rheumatol. 2009 Jul; 21(4):419-24. Kavanaugh A. PMID: 19444117.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    279. The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk. Clin Exp Rheumatol. 2009 May-Jun; 27(3):395-401. Greenberg JD, Fisher MC, Kremer J, Chang H, Rosenstein ED, Kishimoto M, Lee S, Yazici Y, Kavanaugh A, Abramson SB. PMID: 19604430.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    280. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J Rheumatol. 2009 Aug; 36(8):1611-7. Lee SJ, Chang H, Yazici Y, Greenberg JD, Kremer JM, Kavanaugh A. PMID: 19369454.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    281. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010 Feb; 69(2):380-6. Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, Bishai W, Hochberg MC. PMID: 19359261.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    282. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009 Apr; 60(4):976-86. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A. PMID: 19333944.
      View in: PubMed   Mentions: 121     Fields:    Translation:HumansCTClinical Trials
    283. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009 Apr; 60(4):1102-11. Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver R, Kim YH, Steen VD, Firestein GS, Kavanaugh AF, Weisman M, Mayes MD, Collier D, Csuka ME, Simms R, Merkel PA, Medsger TA, Sanders ME, Maranian P, Seibold JR. PMID: 19333948.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    284. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford). 2009 May; 48(5):582-6. Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, Kavanaugh A. PMID: 19307257.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    285. The clinical efficacy of tocilizumab in rheumatoid arthritis. Drugs Today (Barc). 2009 Mar; 45(3):189-97. Mircic M, Kavanaugh A. PMID: 19436841.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    286. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009 Feb 21; 373(9664):633-40. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A. PMID: 19217154.
      View in: PubMed   Mentions: 126     Fields:    Translation:Humans
    287. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis. 2008 Dec; 67 Suppl 3:iii2-25. Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH. PMID: 19022808.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    288. The treatment of psoriatic arthritis and inflammatory spondylitis. Curr Pain Headache Rep. 2008 Dec; 12(6):412-7. Castro-Rueda H, Kavanaugh A. PMID: 18973733.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    289. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009 Jun; 68(6):797-804. Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, Strand V, Vencovsky J, van der Heijde D. PMID: 19015207.
      View in: PubMed   Mentions: 139     Fields:    Translation:HumansCTClinical Trials
    290. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 2008 Nov; 58(11):3309-18. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Grossbard E. PMID: 18975322.
      View in: PubMed   Mentions: 105     Fields:    Translation:Humans
    291. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009 Sep; 68(9):1387-94. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB, McHugh NJ, Nash P, Qureshi AA, Soriano ER, Taylor WJ. PMID: 18952643.
      View in: PubMed   Mentions: 97     Fields:    Translation:Humans
    292. Evaluation of an instrument assessing influence of Gout on health-related quality of life. J Rheumatol. 2008 Dec; 35(12):2406-14. Hirsch JD, Lee SJ, Terkeltaub R, Khanna D, Singh J, Sarkin A, Harvey J, Kavanaugh A. PMID: 18925685.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    293. Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Res Ther. 2008; 10(5):R105. Rosengren S, Wei N, Kalunian KC, Zvaifler NJ, Kavanaugh A, Boyle DL. PMID: 18761748.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    294. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther Clin Risk Manag. 2008 Aug; 4(4):767-75. Hennigan S, Kavanaugh A. PMID: 19209259.
      View in: PubMed   Mentions:
    295. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008 Aug; 58(8):2443-52. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, Mellis SJ. PMID: 18668535.
      View in: PubMed   Mentions: 174     Fields:    Translation:Humans
    296. Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy. Core Evid. 2008 Jul 31; 2(4):295-305. Hennigan S, Ackermann C, Kavanaugh A. PMID: 21221193.
      View in: PubMed   Mentions:
    297. Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol. 2008 Aug; 35(8):1567-75. Sánchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace DJ, Ginzler EM, Sherrer YR, McIlwain HH, Freeman PG, Aranow C, Petri MA, Deodhar AA, Blanton E, Manzi S, Kavanaugh A, Lisse JR, Ramsey-Goldman R, McKay JD, Kivitz AJ, Mease PJ, Winkler AE, Kahl LE, Lee AH, Furie RA, Strand CV, Lou L, Ahmed M, Quarles B, Schwartz KE. PMID: 18634158.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    298. Initiative for quality in psoriasis and psoriatic arthritis. J Rheumatol. 2008 Jul; 35(7):1431-3. Boehncke WH, Adebajo A, Cauli A, Nash P, Salvarani C, Kavanaugh AF. PMID: 18609739.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    299. The pathobiology of psoriatic synovium. Curr Opin Rheumatol. 2008 Jul; 20(4):404-7. Boyle DL, Kavanaugh A. PMID: 18525352.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    300. Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Ann Rheum Dis. 2008 Oct; 67(10):1444-7. Kavanaugh A, Klareskog L, van der Heijde D, Li J, Freundlich B, Hooper M. PMID: 18535115.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    301. Biologic therapy for early rheumatoid arthritis: the latest evidence. Curr Opin Rheumatol. 2008 May; 20(3):314-9. Castro-Rueda H, Kavanaugh A. PMID: 18388524.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    302. The editor's roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol. 2008 Apr 15; 101(8):1119-26. Friedewald VE, Cather JC, Gordon KB, Kavanaugh A, Ridker PM, Roberts WC. PMID: 18394444.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    303. Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. Arthritis Rheum. 2008 Apr 15; 59(4):510-4. Han C, Smolen J, Kavanaugh A, St Clair EW, Baker D, Bala M. PMID: 18383415.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    304. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008 May; 35(5):869-76. Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman DD, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen JS. PMID: 18381786.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    305. Economic burden of psoriatic arthritis. Pharmacoeconomics. 2008; 26(2):121-9. Ackermann C, Kavanaugh A. PMID: 18198932.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    306. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007 Dec; 56(12):4142-50. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. PMID: 18050206.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansCellsCTClinical Trials
    307. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis. 2008 Jun; 67(6):888-91. Taylor WJ, Schumacher HR, Baraf HS, Chapman P, Stamp L, Doherty M, McQueen F, Dalbeth N, Schlesinger N, Furst DE, Vazquez-Mellado J, Mellado JV, Becker MA, Kavanaugh A, Louthrenoo W, Bardin T, Khanna D, Simon LS, Yamanaka H, Choi HK, Zeng X, Strand V, Grainger R, Clegg D, Singh JA, Diaz-Torne C, Boers M, Gow P, Barskova VG. PMID: 18055475.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    308. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin Ther Targets. 2007 Nov; 11(11):1369-84. Ackermann C, Kavanaugh A. PMID: 18028004.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    309. Quality indicators in psoriatic arthritis. Clin Exp Rheumatol. 2007 Nov-Dec; 25(6 Suppl 47):98-101. Kavanaugh A, Ritchlin C, Boehncke WH. PMID: 18021513.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    310. Association of anemia and physical disability among patients with rheumatoid arthritis. J Rheumatol. 2007 Nov; 34(11):2177-82. Han C, Rahman MU, Doyle MK, Bathon JM, Smolen J, Kavanaugh A, Westhovens R, St Clair EW, Baker D, Bala M. PMID: 17937474.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    311. Economic consequences of established rheumatoid arthritis and its treatment. Best Pract Res Clin Rheumatol. 2007 Oct; 21(5):929-42. Kavanaugh A. PMID: 17870036.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    312. Electronic and computer-generated patient questionnaires in standard care. Best Pract Res Clin Rheumatol. 2007 Aug; 21(4):637-47. Lee SJ, Kavanaugh A, Lenert L. PMID: 17678825.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    313. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum. 2007 Aug; 56(8):2698-707. van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, Zhou B, Dooley LT, de Vlam K, Geusens P, Birbara C, Halter D, Beutler A. PMID: 17665424.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    314. International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol. 2007 Aug; 34(8):1740-5. Gladman DD, Inman RD, Cook RJ, Maksymowych WP, Braun J, Davis JC, Landewé RB, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O'Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ, van der Heijde D. PMID: 17659754.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    315. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis. 2008 Mar; 67(3):402-8. Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firestein GS, Kalunian K, Wei N, Boyle DL. PMID: 17644541.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCellsCTClinical Trials
    316. A conversation with Arthur Kavanaugh. Manag Care Interface. 2007 Jul; 20(7):26-7, 30. Kavanaugh A. PMID: 17849730.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    317. International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. J Rheumatol. 2007 Aug; 34(8):1733-9. Gladman DD, Inman RD, Cook RJ, van der Heijde D, Landewé RB, Braun J, Davis JC, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O'Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ, Maksymowych WP. PMID: 17611985.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    318. Outcome measures in psoriatic arthritis. J Rheumatol. 2007 May; 34(5):1159-66. Gladman DD, Mease PJ, Healy P, Helliwell PS, Fitzgerald O, Cauli A, Lubrano E, Krueger GG, van der Heijde D, Veale DJ, Kavanaugh A, Nash P, Ritchlin C, Taylor W, Strand V. PMID: 17477479.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    319. Economic issues with new rheumatologic therapeutics. Curr Opin Rheumatol. 2007 May; 19(3):272-6. Kavanaugh A. PMID: 17414954.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    320. Current treatments for rheumatoid arthritis. Am J Orthop (Belle Mead NJ). 2007 Mar; 36(3 Suppl):4-7. Kavanaugh A. PMID: 17491580.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    321. Rheumatic disease in the elderly: rheumatoid arthritis. Rheum Dis Clin North Am. 2007 Feb; 33(1):57-70. Tutuncu Z, Kavanaugh A. PMID: 17367692.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    322. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther. 2007; 9(5):R103. Han C, Smolen JS, Kavanaugh A, van der Heijde D, Braun J, Westhovens R, Zhao N, Rahman MU, Baker D, Bala M. PMID: 17922913.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    323. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol. 2007 Jan; 34(1):123-9. Cassell SE, Bieber JD, Rich P, Tutuncu ZN, Lee SJ, Kalunian KC, Wu CW, Kavanaugh A. PMID: 17216680.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    324. Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials. Bull NYU Hosp Jt Dis. 2007; 65 Suppl 1:S16-20. Kavanaugh A. PMID: 17708740.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    325. Biologic agents in rheumatology: safety considerations. Rheum Dis Clin North Am. 2006 Dec; 32 Suppl 1:3-10. Lee SJ, Kavanaugh A. PMID: 17410696.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    326. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007 Apr; 66(4):498-505. Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C. PMID: 17114188.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    327. Defining remission in psoriatic arthritis. Clin Exp Rheumatol. 2006 Nov-Dec; 24(6 Suppl 43):S-83-7. Kavanaugh A, Fransen J. PMID: 17083768.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    328. Complexities in defining remission in rheumatic diseases. Clin Exp Rheumatol. 2006 Nov-Dec; 24(6 Suppl 43):S-1-6. Pincus T, Kavanaugh A, Aletaha D, Smolen J. PMID: 17083755.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    329. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol. 2006 Nov; 33(11):2254-9. Kavanaugh A, Antoni C, Mease P, Gladman D, Yan S, Bala M, Zhou B, Dooley LT, Beutler A, Guzzo C, Krueger GG. PMID: 16960923.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    330. Rheumatoid arthritis in dermatology. Clin Dermatol. 2006 Sep-Oct; 24(5):430-7. Hata T, Kavanaugh A. PMID: 16966022.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    331. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol. 2006 Jul; 18(4):347-53. Kavanaugh A, Tutuncu Z, Catalan-Sanchez T. PMID: 16763453.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    332. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis? Nat Clin Pract Rheumatol. 2006 Jul; 2(7):346-7. Kavanaugh A. PMID: 16932716.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    333. Implications of radiographic joint damage in rheumatoid arthritis: comment on the editorial by Weisman. Arthritis Rheum. 2006 Jun; 54(6):2035. Kavanaugh A. PMID: 16732575.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    334. Pharmacoeconomic considerations in the treatment of psoriatic arthritis. Rheumatology (Oxford). 2006 Jul; 45(7):790-1. Kavanaugh A. PMID: 16705044.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    335. Therapies for psoriatic nail disease. A systematic review. J Rheumatol. 2006 Jul; 33(7):1452-6. Cassell S, Kavanaugh AF. PMID: 16724366.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    336. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol. 2006 Jul; 33(7):1417-21. Kavanaugh AF, Ritchlin CT. PMID: 16724373.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    337. B cell targeted therapies: safety considerations. J Rheumatol Suppl. 2006 May; 77:18-23. Kavanaugh AF. PMID: 16652441.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    338. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006 May; 54(5):1390-400. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM. PMID: 16649186.
      View in: PubMed   Mentions: 234     Fields:    Translation:HumansCTClinical Trials
    339. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis. 2006 Oct; 65(10):1373-8. Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, Van Riel PL. PMID: 16644783.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    340. Recent developments in diet and gout. Curr Opin Rheumatol. 2006 Mar; 18(2):193-8. Lee SJ, Terkeltaub RA, Kavanaugh A. PMID: 16462528.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    341. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. Adv Ther. 2006 Mar-Apr; 23(2):208-17. Kavanaugh A. PMID: 16751154.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    342. Biologic therapies for the treatment of asthma. Clin Chest Med. 2006 Mar; 27(1):133-47, vii. Wagelie-Steffen AL, Kavanaugh AF, Wasserman SI. PMID: 16543058.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    343. 4. Autoimmunity, vasculitis, and autoantibodies. J Allergy Clin Immunol. 2006 Feb; 117(2 Suppl Mini-Primer):S445-50. Lee SJ, Kavanaugh A. PMID: 16455344.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    344. The pharmacoeconomics of newer therapeutics for rheumatic diseases. Rheum Dis Clin North Am. 2006 Feb; 32(1):45-56, viii. Kavanaugh A. PMID: 16504820.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    345. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006 Aug; 65(8):1038-43. Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A, Keenan G, Burmester G, Furst DE, Weisman MH, Kalden JR, Smolen J, van der Heijde D. PMID: 16439444.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    346. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006 Sep; 65(9):1226-9. Tutuncu Z, Reed G, Kremer J, Kavanaugh A. PMID: 16414968.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    347. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006 Jan; 54(1):26-37. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. PMID: 16385520.
      View in: PubMed   Mentions: 433     Fields:    Translation:Humans
    348. Macromolecule tumor necrosis factor inhibitors: are more better? J Rheumatol. 2005 Dec; 32(12):2285-7. Kavanaugh AF. PMID: 16331750.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    349. Factors affecting rheumatoid arthritis patients' decisions to participate in clinical trials. J Rheumatol. 2005 Dec; 32(12):2317-25. Lee SJ, Lenert L, Weisman S, Kavanaugh A. PMID: 16331756.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    350. Radiographic benefit without clinical improvement in infliximab-treated patients with rheumatoid arthritis: comment on the article by Smolen et al. Arthritis Rheum. 2005 Dec; 52(12):4044-5; author reply 4045-7. Pincus T, Yazici Y, Yazici H, Kavanaugh AF, Kremer JM, Wolfe F. PMID: 16320353.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    351. A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis. J Rheumatol. 2005 Dec; 32(12):2345-50. Genovese MC, Chakravarty EF, Boyle DL, Tutuncu Z, Thorburn CM, Halilhodzic M, Kroll S, Baughman J, Stewart S, Kavanaugh A. PMID: 16331761.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    352. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis. 2006 Jun; 65(6):753-9. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. PMID: 16308341.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    353. Outcome measures in psoriatic arthritis. J Rheumatol. 2005 Nov; 32(11):2262-9. Gladman DD, Mease PJ, Krueger G, van der Heidje DM, Antoni C, Helliwell PS, Kavanaugh AF, Nash P, Ritchlin CT, Strand CV, Taylor W. PMID: 16265714.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    354. Health economics: implications for novel antirheumatic therapies. Ann Rheum Dis. 2005 Nov; 64 Suppl 4:iv65-9. Kavanaugh A. PMID: 16239392.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    355. Adverse reactions to biologic agents: focus on autoimmune disease therapies. J Allergy Clin Immunol. 2005 Oct; 116(4):900-5. Lee SJ, Kavanaugh A. PMID: 16210067.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    356. Novel therapies for rheumatoid arthritis. Pathophysiology. 2005 Oct; 12(3):217-25. Chang J, Kavanaugh A. PMID: 16099629.
      View in: PubMed   Mentions:
    357. Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatment. J Immune Based Ther Vaccines. 2005 Sep 02; 3:6. Cassell S, Kavanaugh A. PMID: 16138929.
      View in: PubMed   Mentions:
    358. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum. 2005 Sep; 52(9):2693-6. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D. PMID: 16142749.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    359. The assessment of disease activity and outcomes in psoriatic arthritis. Clin Exp Rheumatol. 2005 Sep-Oct; 23(5 Suppl 39):S142-7. Kavanaugh A, Cassell S. PMID: 16273798.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    360. The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis--a systematic review. Clin Exp Rheumatol. 2005 Sep-Oct; 23(5 Suppl 39):S69-76. Riedemann JP, Muñoz S, Kavanaugh A. PMID: 16273788.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    361. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis. 2006 Apr; 65(4):471-7. Kavanaugh A, Antoni C, Krueger GG, Yan S, Bala M, Dooley LT, Beutler A, Guzzo C, Gladman D. PMID: 16096330.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    362. Rheumatic disease in the elderly: rheumatoid arthritis. Clin Geriatr Med. 2005 Aug; 21(3):513-25, vi. Tutuncu Z, Kavanaugh A. PMID: 15911204.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    363. Outcome measures in psoriatic arthritis. Curr Rheumatol Rep. 2005 Jun; 7(3):195-200. Kavanaugh A, Cassell S. PMID: 15918995.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    364. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005 Apr; 52(4):1227-36. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. PMID: 15818699.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansCTClinical Trials
    365. Ethical and practical issues in conducting clinical trials in psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005 Mar; 64 Suppl 2:ii46-8. Kavanaugh A. PMID: 15708936.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    366. What to do with TNF failures. Expert Opin Drug Saf. 2005 Mar; 4(2):149-55. Keystone EC, Kavanaugh A. PMID: 15794709.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    367. OMERACT 7 psoriatic arthritis workshop: synopsis. Ann Rheum Dis. 2005 Mar; 64 Suppl 2:ii115-6. Gladman DD, Strand V, Mease PJ, Antoni C, Nash P, Kavanaugh A. PMID: 15708925.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    368. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005 Aug; 64(8):1150-7. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A. PMID: 15677701.
      View in: PubMed   Mentions: 120     Fields:    Translation:HumansCTClinical Trials
    369. A need for greater reporting of socioeconomic status and race in clinical trials. Ann Rheum Dis. 2004 Dec; 63(12):1700-1. Lee SJ, Kavanaugh A. PMID: 15547101.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    370. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis. J Rheumatol. 2004 Oct; 31(10):1881-4. Kavanaugh A, Cohen S, Cush JJ. PMID: 15468347.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    371. Quantitative documentation of benefit/risk of new therapies for rheumatoid arthritis: patient questionnaires as an optimal measure in standard care. Clin Exp Rheumatol. 2004 Sep-Oct; 22(5 Suppl 35):S26-33. Pincus T, Sokka T, Kavanaugh A. PMID: 15552511.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    372. Internet-based monitoring of patients with rheumatoid arthritis. Clin Exp Rheumatol. 2004 Sep-Oct; 22(5 Suppl 35):S34-8. Lee SJ, Lenert L, Kavanaugh A. PMID: 15552512.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    373. Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for "near remission" of DAS or single measures. Clin Exp Rheumatol. 2004 Sep-Oct; 22(5 Suppl 35):S50-6. Pincus T, Sokka T, Kavanaugh A. PMID: 15552515.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    374. Tuberculosis and opportunistic infections: relevance to biologic agents. Clin Exp Rheumatol. 2004 Sep-Oct; 22(5 Suppl 35):S126-33. Bieber J, Kavanaugh A. PMID: 15552526.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    375. Benefit/risk of therapies for rheumatoid arthritis: underestimation of the "side effects" or risks of RA leads to underestimation of the benefit/risk of therapies. Clin Exp Rheumatol. 2004 Sep-Oct; 22(5 Suppl 35):S2-11. Pincus T, Kavanaugh A, Sokka T. PMID: 15552508.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    376. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004 Sep; 50(9):2858-68. Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE. PMID: 15452837.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    377. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol. 2004 Aug; 31(8):1521-31. Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, Luggen M, Keystone E, Bathon J, Kavanaugh A, Ruderman E, Coleman P, Curtis D, Kopp E, Kantor S, Weisman M, Waltuck J, Lindsley HB, Markenson J, Crawford B, Fernando I, Simpson K, Strand V. PMID: 15290730.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    378. Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis. Ann Rheum Dis. 2005 Jan; 64(1):52-5. Breedveld FC, Han C, Bala M, van der Heijde D, Baker D, Kavanaugh AF, Maini RN, Lipsky PE. PMID: 15286005.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    379. The role of interleukin-1 in bone resorption in rheumatoid arthritis. Rheumatology (Oxford). 2004 Jun; 43 Suppl 3:iii10-iii16. Strand V, Kavanaugh AF. PMID: 15150427.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    380. Disease measures in evaluating the effect of anti-TNF therapy and predicting clinical outcome. Rheumatology (Oxford). 2004 May; 43(5):682-3. Tutuncu Z, Bansal C, Kavanaugh A. PMID: 15103044.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    381. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol. 2004 May; 31(5):849-55. Kavanaugh A, Han C, Bala M. PMID: 15124242.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    382. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004 May; 50(5):1400-11. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK. PMID: 15146409.
      View in: PubMed   Mentions: 304     Fields:    Translation:HumansCTClinical Trials
    383. Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheum Dis Clin North Am. 2004 May; 30(2):257-70, v. Bieber J, Kavanaugh A. PMID: 15172039.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    384. Cutting edge diagnostics in rheumatology: the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. Arthritis Rheum. 2004 Apr 15; 51(2):291-8. Wiik AS, Gordon TP, Kavanaugh AF, Lahita RG, Reeves W, van Venrooij WJ, Wilson MR, Fritzler M. PMID: 15077275.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    385. A web-compatible instrument for measuring self-reported disease activity in arthritis. J Rheumatol. 2004 Feb; 31(2):223-8. Athale N, Sturley A, Skoczen S, Kavanaugh A, Lenert L. PMID: 14760788.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    386. Evidence-based use of rheumatologic laboratory tests. Arch Intern Med. 2004 Jan 12; 164(1):109. Kavanaugh AF. PMID: 14718337.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    387. Nutrient intake and diet quality in patients with systemic lupus erythematosus on a culturally sensitive cholesterol lowering dietary program. J Rheumatol. 2004 Jan; 31(1):71-5. Shah M, Adams-Huet B, Kavanaugh A, Coyle Y, Lipsky P. PMID: 14705221.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    388. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis. 2003 Nov; 62 Suppl 2:ii2-9. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Dougados M, Emery P, Gibofsky A, Kavanaugh AF, Keystone EC, Klareskog L, Russell AS, van de Putte LB, Weisman MH, Kavenaugh AF. PMID: 14532138.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    389. Cigarette smoking, TB, and TNF inhibitors. Ann Rheum Dis. 2003 Nov; 62(11):1118-9. Bieber J, Kavanaugh A. PMID: 14583580.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    390. Quantitative biomarker analysis of synovial gene expression by real-time PCR. Arthritis Res Ther. 2003; 5(6):R352-60. Boyle DL, Rosengren S, Bugbee W, Kavanaugh A, Firestein GS. PMID: 14680510.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCells
    391. Pharmacological treatment of established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2003 Oct; 17(5):811-29. Lee SJ, Kavanaugh A. PMID: 12915159.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    392. Secondary immune deficiencies associated with biological therapeutics. Curr Allergy Asthma Rep. 2003 Sep; 3(5):389-95. Lee SJ, Yedla P, Kavanaugh A. PMID: 12906774.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    393. The safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheumatol. 2003 Sep-Oct; 21(5 Suppl 31):S203-8. Kavanaugh A, Keystone EC. PMID: 14969079.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    394. Reading and interpreting economic evaluations in rheumatoid arthritis: an assessment of selected instruments for critical appraisal. J Rheumatol. 2003 Aug; 30(8):1739-47. Weisman MH, Gano AD, Gabriel SE, Hochberg MC, Kavanaugh A, Ofman JJ, Prashker M, Suarez-Almazor ME, Yelin E, Nakelsky SD, Croft JD. PMID: 12913929.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    395. Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial. J Rheumatol. 2003 Mar; 30(3):449-54. Kavanaugh A, Genovese M, Baughman J, Kivitz A, Bulpitt K, Olsen N, Weisman M, Matteson E, Furst D, van Vollenhoven R, Anderson J, Cohen S, Wei N, Meijerink J, Jacobs C, Mocci S. PMID: 12610799.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    396. Anti-TNF therapy for other inflammatory conditions. Clin Exp Rheumatol. 2002 Nov-Dec; 20(6 Suppl 28):S146-51. Tutuncu Z, Morgan GJ, Kavanaugh A. PMID: 12463467.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    397. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis. 2002 Nov; 61 Suppl 2:ii2-7. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, Bijlsma JW, Burmester GR, Cronstein B, Keystone EC, Kavanaugh A, Klareskog L. PMID: 12379612.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    398. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum. 2002 Oct 15; 47(5):546-55. Kavanaugh AF, Solomon DH. PMID: 12382306.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    399. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med. 2002 Oct 01; 113(5):400-8. Wong JB, Singh G, Kavanaugh A. PMID: 12401535.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    400. Effect of a culturally sensitive cholesterol lowering diet program on lipid and lipoproteins, body weight, nutrient intakes, and quality of life in patients with systemic lupus erythematosus. J Rheumatol. 2002 Oct; 29(10):2122-8. Shah M, Kavanaugh A, Coyle Y, Adams-Huet B, Lipsky PE. PMID: 12375321.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    401. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Jun; 46(6):1451-9. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC. PMID: 12115174.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCTClinical Trials
    402. Combination cytokine therapy: the next generation of rheumatoid arthritis therapy? Arthritis Rheum. 2002 Feb; 47(1):87-92. Kavanaugh A. PMID: 11932883.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    403. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). Ann Rheum Dis. 2001 Nov; 60 Suppl 3:iii2-5. Furst DE, Keystone EC, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, Burmester GR, Crofford LJ, Kavanaugh A. PMID: 11890647.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    404. The utility of immunologic laboratory tests in patients with rheumatic diseases. Arthritis Rheum. 2001 Oct; 44(10):2221-3. Kavanaugh A. PMID: 11665961.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    405. Evaluating severity and status in rheumatoid arthritis. J Rheumatol. 2001 Jun; 28(6):1453-62. Wolfe F, O'Dell JR, Kavanaugh A, Wilske K, Pincus T. PMID: 11409143.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    406. Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol. 2001 Jun; 28(6):1423-30. Wolfe F, Cush JJ, O'Dell JR, Kavanaugh A, Kremer JM, Lane NE, Moreland LW, Paulus HE, Pincus T, Russell AS, Wilskie KR. PMID: 11409141.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    407. Biologics in the treatment of rheumatoid arthritis: mechanisms of action. Curr Dir Autoimmun. 2001; 3:240-73. Kavanaugh A, Lipsky P. PMID: 11791469.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    408. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000). Ann Rheum Dis. 2000 Nov; 59 Suppl 1:i1-2. Furst DE, Breedveld FC, Burmester GR, Crofford JJ, Emery P, Feldmann M, Kalden JR, Kavanaugh AF, Keystone EC, Klareskog LG, Lipsky PE, Maini RN, Russell AS, Scott DL, Smolen JS, Van de Putte LB, Visher TL, Weisman MH. PMID: 11053077.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    409. Development and initial evaluation of a culturally sensitive cholesterol-lowering diet program for Mexican and African American patients with systemic lupus erythematosus. Arthritis Care Res. 2000 Aug; 13(4):205-12. Shah M, Coyle Y, Kavanaugh A, Adams-Huet B, Lipsky PE. PMID: 14635275.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    410. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000 Apr; 27(4):841-50. Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. PMID: 10782805.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    411. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med. 2000 Jan; 124(1):71-81. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. PMID: 10629135.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    412. The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies. Rheumatology (Oxford). 1999 Nov; 38 Suppl 2:41-4. Lipsky PE, Kavanaugh A. PMID: 10646490.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    413. Access to disease modifying treatments for rheumatoid arthritis patients. Ann Rheum Dis. 1999 Nov; 58 Suppl 1:I129-30. Furst DE, Breedveld FC, Burmester GR, Crofford L, Emery P, Feldman M, Kalden JR, Kavanaugh A, Keystone E, Lipsky PE, Maini RN, Moreland L, Smolen JS, Van De Putte L, Vischer T, Weinblatt M, Weissman M. PMID: 10577989.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    414. Discussion. Section 2: immunomodulatory intervention. Drugs Today (Barc). 1999 Apr-May; 35(4-5):405-6. Catchpole B, Kavanaugh A, Hobbs K, Choy EH. PMID: 14664237.
      View in: PubMed   Mentions:    Fields:    
    415. An overview of immunomodulatory intervention in rheumatoid arthritis. Drugs Today (Barc). 1999 Apr-May; 35(4-5):275-86. Kavanaugh A. PMID: 12973432.
      View in: PubMed   Mentions: 1     Fields:    
    416. The role of the laboratory in the evaluation of rheumatic diseases. Clin Cornerstone. 1999; 2(2):11-25. Kavanaugh A. PMID: 10689541.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    417. Inhibitors of tumor necrosis factor in rheumatoid arthritis: Will that dog hunt? J Rheumatol. 1998 Nov; 25(11):2049-53. Kavanaugh A, Cohen S, Cush J. PMID: 9818641.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    418. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am. 1998 Aug; 24(3):593-614. Kavanaugh AF. PMID: 9710889.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    419. Lipid profiles in patients with rheumatoid arthritis. Ann Rheum Dis. 1998 Mar; 57(3):175. Kavanaugh A. PMID: 9640139.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    420. Rheumatoid arthritis in the elderly: is it a different disease? Am J Med. 1997 Dec 29; 103(6A):40S-48S. Kavanaugh AF. PMID: 9455968.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    421. An evidence-based medicine approach to the diagnosis and management of musculoskeletal complaints. Am J Med. 1997 Dec 29; 103(6A):3S-6S. Ellrodt AG, Cho M, Cush JJ, Kavanaugh AF, Lipsky PE. PMID: 9455962.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    422. Risk factors for early work disability in systemic lupus erythematosus: results from a multicenter study. Arthritis Rheum. 1997 Dec; 40(12):2199-206. Partridge AJ, Karlson EW, Daltroy LH, Lew RA, Wright EA, Fossel AH, Straaton KV, Stern SH, Kavanaugh AF, Roberts WN, Liang MH. PMID: 9416857.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    423. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum. 1997 May; 40(5):849-53. Kavanaugh AF, Schulze-Koops H, Davis LS, Lipsky PE. PMID: 9153545.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimals
    424. Elevated cytokine messenger RNA levels in the peripheral blood of patients with rheumatoid arthritis suggest different degrees of myeloid cell activation. Arthritis Rheum. 1997 Apr; 40(4):639-47. Schulze-Koops H, Davis LS, Kavanaugh AF, Lipsky PE. PMID: 9125245.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    425. [Not Available]. BioDrugs. 1997 Feb; 7(2):119-33. Kavanaugh A. PMID: 18031086.
      View in: PubMed   Mentions: 1     Fields:    
    426. Hydroxychloroquine Effects on Lipoprotein Profiles (the HELP trial): A Double-Blind, Randomized, Placebo-Controlled, Pilot Study In Patients With Systemic Lupus Erythematosus. J Clin Rheumatol. 1997 Feb; 3(1):3-8. Kavanaugh A, Adams-Huet B, Jain R, Denke M, McFarlin J. PMID: 19078110.
      View in: PubMed   Mentions: 12     Fields:    
    427. The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum. 1997 Jan; 40(1):47-56. Karlson EW, Daltroy LH, Lew RA, Wright EA, Partridge AJ, Fossel AH, Roberts WN, Stern SH, Straaton KV, Wacholtz MC, Kavanaugh AF, Grosflam JM, Liang MH. PMID: 9008599.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    428. Flare of psoriasis and psoriatic arthritis following treatment with granulocyte colony-stimulating factor. Am J Med. 1996 Nov; 101(5):567-8. Kavanaugh A. PMID: 8948284.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    429. Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1). Clin Exp Immunol. 1996 Nov; 106(2):190-6. Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS. PMID: 8918562.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    430. Adhesion molecules as therapeutic targets in the treatment of allergic and immunologically mediated diseases. Clin Immunol Immunopathol. 1996 Sep; 80(3 Pt 2):S15-22. Kavanaugh A. PMID: 8811059.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    431. Physician-assisted suicide. N Engl J Med. 1996 Aug 15; 335(7):518; author reply 519-20. Kavanaugh A. PMID: 8676955.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    432. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol. 1996 Aug; 23(8):1338-44. Kavanaugh AF, Davis LS, Jain RI, Nichols LA, Norris SH, Lipsky PE. PMID: 8856611.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    433. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Semin Arthritis Rheum. 1996 Apr; 25(5):297-307. Kavanaugh A, Heudebert G, Cush J, Jain R. PMID: 8778986.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    434. Folic acid and methotrexate in rheumatoid arthritis. Ann Intern Med. 1996 Jan 01; 124(1 Pt 1):73; author reply 74. Kavanaugh A, Kavanaugh D. PMID: 7503485.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    435. Fibromyalgia or multi-organ dysesthesia? Arthritis Rheum. 1996 Jan; 39(1):180-1. Kavanaugh AF. PMID: 8546733.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    436. Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol. 1995 Nov 15; 155(10):5029-37. Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS. PMID: 7594511.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    437. Rotator cuff dysfunction in patients with rheumatoid arthritis. J Clin Rheumatol. 1995 Oct; 1(5):274-9. Kavanaugh A, Eshaghi N, Cush J, Awad R. PMID: 19077997.
      View in: PubMed   Mentions:    Fields:    
    438. Biologic interventions in rheumatoid arthritis. Rheum Dis Clin North Am. 1995 Aug; 21(3):797-816. Cush JJ, Kavanaugh AF. PMID: 8619100.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    439. Central nervous system angiopathy associated with cocaine abuse. J Rheumatol. 1995 Apr; 22(4):780-2. Martin K, Rogers T, Kavanaugh A. PMID: 7791183.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    440. Induction of persistent T cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis. J Immunol. 1995 Apr 01; 154(7):3525-37. Davis LS, Kavanaugh AF, Nichols LA, Lipsky PE. PMID: 7897232.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    441. Danazol therapy in thrombocytopenia associated with the antiphospholipid antibody syndrome. Ann Intern Med. 1994 Nov 15; 121(10):767-8. Kavanaugh A. PMID: 7944055.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    442. Dyslipoproteinaemia in a subset of patients with rheumatoid arthritis. Ann Rheum Dis. 1994 Aug; 53(8):551-2. Kavanaugh A. PMID: 7944646.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    443. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. 1994 Jul; 37(7):992-9. Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA, Lipsky PE. PMID: 7912930.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCellsCTClinical Trials
    444. Inhibition of the transendothelial migration of human T lymphocytes by prostaglandin E2. J Immunol. 1994 Jun 15; 152(12):5703-13. Oppenheimer-Marks N, Kavanaugh AF, Lipsky PE. PMID: 8207201.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    445. Evaluation of patients with suspected immunodeficiency. Am Fam Physician. 1994 Apr; 49(5):1167-72. Kavanaugh A. PMID: 8154404.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    446. Massive eosinophilic synovitis and reactive arthritis associated with filarial infection. Ann Rheum Dis. 1994 Apr; 53(4):281-2. Kohem CL, Kristiansen SV, Kavanaugh AF. PMID: 8203962.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    447. Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. J Rheumatol. 1992 Oct; 19(10):1625-7. Vasquez S, Kavanaugh AF, Schneider NR, Wacholtz MC, Lipsky PE. PMID: 1464880.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    448. Role of CD11/CD18 in adhesion and transendothelial migration of T cells. Analysis utilizing CD18-deficient T cell clones. J Immunol. 1991 Jun 15; 146(12):4149-56. Kavanaugh AF, Lightfoot E, Lipsky PE, Oppenheimer-Marks N. PMID: 1710241.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    449. Immunoglobulin deficiency syndromes and therapy. J Allergy Clin Immunol. 1991 Jan; 87(1 Pt 1):1-17. Huston DP, Kavanaugh AF, Rohane PW, Huston MM. PMID: 1704022.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    450. Variable expression of IgG2 deficiency. J Allergy Clin Immunol. 1990 Jul; 86(1):4-10. Kavanaugh AF, Huston DP. PMID: 2142499.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    451. Wegener's granulomatosis presenting with unilateral parotid enlargement. Am J Med. 1988 Nov; 85(5):741-2. Kavanaugh AF, Huston DP. PMID: 3189382.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    452. Cyclosporine therapy of central nervous system sarcoidosis. Am J Med. 1987 Feb; 82(2):387. Kavanaugh AF, Andrew SL, Cooper B, Lawrence EC, Huston DP. PMID: 3812543.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    Arthur's Networks
    Concepts (743)
    Derived automatically from this person's publications.
    _
    Co-Authors (44)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _